0001600132-23-000018.txt : 20230306 0001600132-23-000018.hdr.sgml : 20230306 20230306083049 ACCESSION NUMBER: 0001600132-23-000018 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20230303 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230306 DATE AS OF CHANGE: 20230306 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bellerophon Therapeutics, Inc. CENTRAL INDEX KEY: 0001600132 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473116175 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36845 FILM NUMBER: 23707665 BUSINESS ADDRESS: STREET 1: 184 LIBERTY CORNER ROAD, SUITE 302 CITY: WARREN STATE: NJ ZIP: 07059 BUSINESS PHONE: 908-574-4770 MAIL ADDRESS: STREET 1: 184 LIBERTY CORNER ROAD, SUITE 302 CITY: WARREN STATE: NJ ZIP: 07059 FORMER COMPANY: FORMER CONFORMED NAME: Bellerophon Therapeutics LLC DATE OF NAME CHANGE: 20140213 8-K 1 blph-20230303x8k.htm 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 3, 2023

Bellerophon Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)


Delaware	001-36845	47-3116175
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)


184 Liberty Corner Road, Suite 302 Warren, New Jersey		07059
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (908) 574-4770

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par value per share	BLPH	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


	☐	Emerging growth company
	☐	If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 1.01. Entry into a Material Definitive Agreement.

On March 3, 2023, Bellerophon Therapeutics, Inc. (the “Company”) entered into a subscription agreement with an institutional investor, pursuant to which the Company agreed to issue and sell in a registered direct offering (the “Offering”) (i) an aggregate of 718,474 shares (the “Shares”) of the Company’s common stock, $0.01 par value per share (“Common Stock”) and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 1,781,526 shares of Common Stock. The Shares will be sold to the purchasers at a price per share of $2.00 per share. The Pre-Funded Warrants will be sold at an offering price of $1.99 per Pre-Funded Warrant, which represents the per share offering price for the Common Stock less a $0.01 per share exercise price for each such Pre-Funded Warrant. The net proceeds from the Offering, after deducting estimated expenses, are expected to be approximately $5 million.

The Company intends to use the proceeds of this $5 million offering to complete the Company’s REBUILD Phase 3 study and for working capital and general corporate purposes. The REBUILD study is a Phase 3, randomized, double-blind, placebo-controlled dose escalation and verification clinical trial evaluating the safety and efficacy of pulsed inhaled nitric oxide (iNO) in patients at risk for pulmonary hypertension associated with pulmonary fibrosis on long-term oxygen therapy. With a total of 145 patients fully enrolled, the study is powered >90%, (p-value of 0.01) for the primary endpoint of a change in MVPA measured by actigraphy based on the results from Phase 2. The Company expects to report topline data in mid-2023.

The Subscription Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company, other obligations of the parties and termination provisions. No underwriter or placement agent participated in the Offering.

The Pre-Funded Warrants are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. A holder of Pre-Funded Warrants may increase or decrease this percentage, but not in excess of 19.99%, by providing at least 61 days’ prior notice to the Company.

The Offering is being made pursuant to the Company’s shelf registration statement previously filed with the Securities and Exchange Commission (the “SEC”), originally filed on June 26, 2020 (File No. 333-239473), which the SEC declared effective on July 2, 2020, and a related prospectus supplement.

The Company expects to close the Offering on March 7, 2023, subject to the satisfaction of customary closing conditions.

The Subscription Agreement is filed as Exhibit 10.1 to this Current Report on Form 8-K and the foregoing description of the terms of the Subscription Agreement is qualified in its entirety by reference to such exhibit. The form of Pre-Funded Warrant is filed as Exhibit 4.1 to this Current Report on Form 8-K and the foregoing description of the terms of the Pre-Funded Warrants is qualified in its entirety by reference to such exhibit. A copy of the opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., relating to the legality of the issuance and sale of the Common Stock in the Offering, is filed with this Current Report on Form 8-K as Exhibit 5.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:


Exhibit No.		Description
4.1		Form of Pre-Funded Warrant
5.1		Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
10.1		Subscription Agreement, dated as of March 3, 2023, by and among Bellerophon Therapeutics, Inc. and the purchaser identified on the signature pages thereto.
23.1		Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1)
104		Cover Page Interactive Data File (Formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



	BELLEROPHON THERAPEUTICS, INC.

Date: March 6, 2023	By:	/s/ Peter Fernandes
		Name: Peter Fernandes Title: Chief Executive Officer

EX-4.1 2 blph-20230303xex4d1.htm EX-4.1

Exhibit 4.1

Form of Pre-Funded Warrant

Bellerophon Therapeutics, Inc.
FORM OF WARRANT TO PURCHASE COMMON STOCK

Number of Shares: 1,781,526

Warrant No. [ ]

Original Issue Date: March [ ], 2023

Bellerophon Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company up to a total of 1,781,526 shares of common stock, $0.01 par value per share (the “Common Stock”), of the Company (each such share, a “Warrant Share” and all such shares, the “Warrant Shares”) at an exercise price per share equal to $0.01 per share (as adjusted from time to time as provided in Section 9 herein, the “Exercise Price”) upon surrender of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”) at any time and from time to time on or after the date hereof (the “Original Issue Date”), subject to the following terms and conditions:

1. Definitions. For purposes of this Warrant, the following terms shall have the following meanings:

(a) “Affiliate” means any Person directly or indirectly controlled by, controlling or under common control with, a Holder, as such terms are used in and construed under Rule 405 under the Securities Act, but only for so long as such control shall continue.

(b) “Commission” means the United States Securities and Exchange Commission.

(c) “Closing Sale Price” means, for any security as of any date, the last trade price for such security on the Principal Trading Market for such security, as reported by Bloomberg L.P., or, if such Principal Trading Market begins to operate on an extended hours basis and does not designate the last trade price, then the last trade price of such security prior to 4:00 P.M., New York City time, as reported by Bloomberg L.P., or if the security is not listed for trading on a national securities exchange or other trading market on the relevant date, the last quoted bid price for the security in the over-the-counter market on the relevant date as reported by OTC Markets Group Inc. (or a similar organization or agency succeeding to its functions of reporting prices). If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then the Board of Directors of the Company shall use its good faith judgment to determine the fair market value. The Board of Directors’ determination shall be binding upon all parties absent demonstrable error. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.

(d) “Principal Trading Market” means the national securities exchange or other trading market on which the Common Stock is primarily listed on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Capital Market.

(e) “Registration Statement” means the Company’s Registration Statement on Form S-3 (Registration No. 333-239473).

(f) “Securities Act” means the Securities Act of 1933, as amended.

(g) “Trading Day” means any weekday on which the Principal Trading Market is open for trading. If the Common Stock is not listed or admitted for trading, “Trading Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in New York City are authorized or required by law or other governmental action to close.

(h) “Transfer Agent” means Computershare Trust Company, N.A., the Company’s transfer agent and registrar for the Common Stock, and any successor appointed in such capacity.

2. Issuance of Securities; Registration of Warrants. The Warrant, as initially issued by the Company, is offered and sold pursuant to the Registration Statement. As of the Original Issue Date, the Warrant Shares are issuable under the Registration Statement. Accordingly, the Warrant and, assuming issuance pursuant to the Registration Statement or an exchange meeting the requirements of Section 3(a)(9) of the Securities Exchange Act of 1934 (the “Exchange Act”) as in effect on the Original Issue Date, the Warrant Shares are not “restricted securities” under Rule 144 promulgated under the Securities Act. The Company shall register ownership of this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any assignee to which this Warrant is assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

3. Registration of Transfers. Subject to compliance with all applicable securities laws, the Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes (if any). Upon any such registration or transfer, a new warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a “New Warrant”) evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue and deliver at the Company’s own expense any New Warrant under this Section 3. Until due presentment for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder for all purposes, and the Company shall not be affected by any notice to the contrary.

4. Exercise and Duration of Warrants.

(a) All or any part of this Warrant shall be exercisable by the registered Holder in any manner permitted by this Warrant at any time and from time to time on or after the Original Issue Date.

(b) The Holder may exercise this Warrant by delivering to the Company (i) an exercise notice, in the form attached as Schedule 1 hereto (the “Exercise Notice”), completed and duly signed, and (ii) payment of the Exercise Price for the number of Warrant Shares as to which this Warrant is being exercised (which may take the form of a “cashless exercise” if so indicated in the Exercise Notice pursuant to Section 10 below). The date on which such exercise notice is delivered to the Company (as determined in accordance with the notice provisions hereof) is an “Exercise Date.” The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

5. Delivery of Warrant Shares.

(a) Upon exercise of this Warrant, the Company shall promptly (but in no event later than two Trading Days after the Exercise Date), upon the request of the Holder, cause the Transfer Agent to credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such exercise to the Holder’s or its designee’s balance account with The Depository Trust Company (“DTC”) through its Deposit Withdrawal Agent Commission system, or if the Transfer Agent is not participating in the Fast Automated Securities Transfer Program (the “FAST Program”) or if the certificates are required to bear a legend regarding restriction on transferability, issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise. The Holder, or any natural person or legal entity (each, a “Person”) so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date such Warrant Shares are credited to the Holder’s DTC account or the date of delivery of the certificates evidencing such Warrant Shares, as the case may be.

(b) To the extent permitted by law, the Company’s obligations to cause the Transfer Agent to issue and deliver Warrant Shares in accordance with and subject to the terms hereof (including the limitations set forth in Section 11 below) are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the

Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Nothing herein shall limit the Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

6. Charges, Taxes and Expenses. Issuance and delivery of certificates for shares of Common Stock, if any, upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; provided, however, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or the Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof.

7. Replacement of Warrant. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case) and, in each case, a customary and reasonable indemnity and surety bond, if requested by the Company. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company’s obligation to issue the New Warrant.

8. Reservation of Warrant Shares. The Company covenants that it will, at all times while this Warrant is outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into account the adjustments and restrictions of Section 9). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and non-assessable. The Company will take all such action as may be reasonably necessary to assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed. The Company further covenants that it will not, without the prior written consent of the Holder, take any actions to increase the par value of the Common Stock at any time while this Warrant is outstanding.

9. Certain Adjustments. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to time as set forth in this Section 9.

(a) Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding, (i) pays a stock dividend on its Common Stock or otherwise makes a distribution on any class of capital stock issued and outstanding on the Original Issue Date and in accordance with the terms of such stock on the Original Issue Date or as amended, as described in the Registration Statement, that is payable in shares of Common Stock, (ii) subdivides its outstanding shares of Common Stock into a larger number of shares of Common Stock, (iii) combines its outstanding shares of Common Stock into a smaller number of shares of Common Stock or (iv) issues by reclassification of shares of capital stock any additional shares of Common Stock of the Company, then in each such case the Exercise Price shall be multiplied by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately before such event and the denominator of which shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to clause (i) of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution, provided, however, that if such record date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the Exercise Price shall be recomputed accordingly as of the close of business on such record date and thereafter the Exercise Price shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends. Any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately after the effective date of such subdivision or combination.

(b) Pro Rata Distributions. If the Company, at any time while this Warrant is outstanding, distributes to all holders of Common Stock for no consideration (i) evidences of its indebtedness, (ii) any security (other than a distribution of Common Stock covered by the preceding paragraph), (iii) rights or warrants to subscribe for or purchase any security, or (iv) cash or any other asset (in each case, a “Distribution”), other than a reclassification as to which Section 9(c) applies, then in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the ownership limitation set forth in Section 11(a) hereof) immediately before the date of

which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined for the participation in such Distribution; provided, however, to the extent that the Holder’s right to participate in any such Distribution would result in the Holder exceeding the ownership limitation set forth in Section 11(a) hereof, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until the earlier of (i) such time, if ever, as the delivery to such Holder of such portion would not result in the Holder exceeding the ownership limitation set forth in Section 11(a) hereof and (ii) such time as the Holder has exercised this Warrant.

(c) Fundamental Transactions. If, at any time while this Warrant is outstanding (i) the Company effects any merger or consolidation of the Company with or into another Person, in which the Company is not the surviving entity and in which the stockholders of the Company immediately prior to such merger or consolidation do not own, directly or indirectly, at least 50% of the voting power of the surviving entity immediately after such merger or consolidation, (ii) the Company effects any sale to another Person of all or substantially all of its assets in one transaction or a series of related transactions, (iii) pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of capital stock tender shares representing more than 50% of the voting power of the capital stock of the Company and the Company or such other Person, as applicable, accepts such tender for payment, (iv) the Company consummates a stock purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the voting power of the capital stock of the Company (except for any such transaction in which the stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such Person immediately after the transaction) or (v) the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by Section 9(a) above) (in any such case, a “Fundamental Transaction”), then following such Fundamental Transaction the Holder shall have the right to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant without regard to any limitations on exercise contained herein (the “Alternate Consideration”). The Company shall not effect any Fundamental Transaction in which the Company is not the surviving entity or the Alternate Consideration includes securities of another Person unless (i) the Alternate Consideration is solely cash and the Company provides for the simultaneous “cashless exercise” of this Warrant pursuant to Section 10 below or (ii) prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity or other Person (including any purchaser of assets of the Company) shall assume the obligation to deliver to the Holder such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of this paragraph (c) shall similarly apply to subsequent transactions analogous of a Fundamental Transaction type.

(d) Number of Warrant Shares. Simultaneously with any adjustment to the Exercise Price pursuant to Section 9 (including any adjustment to the Exercise Price that would have been effected but for the final sentence in this paragraph (d)), the number of Warrant Shares that may be purchased upon exercise of this Warrant shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the increased or decreased number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment. Notwithstanding the foregoing, in no event may the Exercise Price be adjusted below the par value of the Common Stock then in effect.

(e) Calculations. All calculations under this Section 9 shall be made to the nearest one-hundredth of one cent or the nearest share, as applicable.

(f) Notice of Adjustments. Upon the occurrence of each adjustment pursuant to this Section 9, the Company at its expense will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Company’s Transfer Agent.

(g) Notice of Corporate Events. If, while this Warrant is outstanding, the Company (i) declares a dividend or any other distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any subsidiary, (ii) authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company, then, except if such notice and the contents thereof shall be deemed to constitute material non-public information, the Company shall deliver to the Holder a notice of such transaction at least ten (10) days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction; provided, however, that the failure to deliver such notice or any defect therein shall not

affect the validity of the corporate action required to be described in such notice. In addition, if while this Warrant is outstanding, the Company authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by Section 9(c), other than a Fundamental Transaction under clause (iii) of Section 9(c), then, except if such notice and the contents thereof shall be deemed to constitute material non-public information, the Company shall deliver to the Holder a notice of such Fundamental Transaction at least ten (10) days prior to the date such Fundamental Transaction is consummated. Holder agrees to maintain any information disclosed pursuant to this Section 9(g) in confidence until such information is publicly available, and shall comply with applicable law with respect to trading in the Company’s securities following receipt of any such information.

10. Payment of Cashless Exercise Price. Notwithstanding anything contained herein to the contrary, the Holder may, in its sole discretion, satisfy its obligation to pay the Exercise Price through a “cashless exercise,” in which event the Company shall issue to the Holder the number of Warrant Shares in an exchange of securities effected pursuant to Section 3(a)(9) of the Securities Act as determined as follows:

X = Y [(A-B)/A]

where:

“X” equals the number of Warrant Shares to be issued to the Holder;

“Y” equals the total number of Warrant Shares with respect to which this Warrant is then being exercised;

“A” equals the Closing Sale Price per share of Common Stock as of the Trading Day on the date immediately preceding the Exercise Date; and

“B” equals the Exercise Price per Warrant Share then in effect on the Exercise Date.

For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in such a “cashless exercise” transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued (provided that the Commission continues to take the position that such treatment is proper at the time of such exercise). In the event that the Registration Statement or another registration statement registering the issuance of Warrant Shares is, for any reason, not effective at the time of exercise of this Warrant, then the Warrant may only be exercised through a cashless exercise, as set forth in this Section 10.

In no event will the exercise of this Warrant be settled in cash.

11. Limitations on Exercise.

(a) Notwithstanding anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and the Holder shall not be entitled to exercise this Warrant for a number of Warrant Shares in excess of that number of Warrant Shares which, upon giving effect or immediately prior to such exercise, would cause (i) the aggregate number of shares of Common Stock beneficially owned by the Holder, its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act to exceed 9.99% (the “Maximum Percentage”) of the total number of issued and outstanding shares of Common Stock of the Company following such exercise, or (ii) the combined voting power of the securities of the Company beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act to exceed 9.99% of the combined voting power of all of the securities of the Company then outstanding following such exercise. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) the Company’s most recent Form 10-Q or Form 10-K, as the case may be, filed with the Commission prior to the Exercise Date, (y) a more recent public announcement by the Company or (z) any other notice by the Company or its Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written request of the Holder, the Company shall within three Trading Days confirm in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder since the date as of which such number of outstanding shares of Common Stock was reported. By written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other percentage, not in excess of 19.99%, specified in such notice; provided that any such increase or decrease will not be effective until the 61st day after such notice is delivered to the Company. For purposes of this Section 11(a), the aggregate number of shares of Common Stock or voting securities beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder’s for purposes of

Section 13(d) of the Exchange Act shall include the shares of Common Stock issuable upon the exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (x) exercise of the remaining unexercised and non-cancelled portion of this Warrant by the Holder and (y) exercise or conversion of the unexercised, non-converted or non-cancelled portion of any other securities of the Company that do not have voting power (including without limitation any securities of the Company which would entitle the holder thereof to acquire at any time Common Stock, including without limitation any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock), is subject to a limitation on conversion or exercise analogous to the limitation contained herein and is beneficially owned by the Holder or any of its Affiliates and other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act.

(b) This Section 11 shall not restrict the number of shares of Common Stock which a Holder may receive or beneficially own in order to determine the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated in Section 9(c) of this Warrant.

12. No Fractional Shares. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number.

13. Notices. Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via confirmed e-mail prior to 5:30 P.M., New York City time, on a Trading Day, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile or confirmed e-mail on a day that is not a Trading Day or later than 5:30 P.M., New York City time, on any Trading Day, (iii) the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service specifying next business day delivery, or (iv) upon actual receipt by the Person to whom such notice is required to be given, if by hand delivery. The addresses, facsimile numbers and e-mail addresses for such communications shall be:

If to the Company:

Bellerophon Therapeutics, Inc.

184 Liberty Corner Road, Suite 302

Warren, New Jersey 07059

Attention: Nicholas Laccona, Principal Financial Officer and Principal Accounting Officer

e-mail: nicholas.laccona@bellerophon.com

If to the Holder, to its address or e-mail address set forth herein or on the books and records of the Company.

Or, in each of the above instances, to such other address, facsimile number or e-mail address as the recipient party has specified by written notice given to each other party at least five (5) days prior to the effectiveness of such change.

14. Warrant Agent. The Company shall initially serve as warrant agent under this Warrant. Upon ten (10) days’ notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder’s last address as shown on the Warrant Register.

15. Miscellaneous.

(a) No Rights as a Stockholder. The Holder, solely in such Person’s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person’s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings,

receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.

(b) Authorized Shares. Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (a) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (b) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and non-assessable Warrant Shares upon the exercise of this Warrant, and (c) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant.

(c) Successors and Assigns. Subject to compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction. This Warrant shall be binding on and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns.

(d) Amendment and Waiver. Except as otherwise provided herein, the provisions of the Warrants may be amended and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Holder.

(e) Acceptance. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein.

(f) Governing Law; Jurisdiction. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY.

(g) Headings. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof.

(h) Severability. In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above.

Bellerophon Therapeutics, Inc.

By:

Name:

Title:

SCHEDULE 1

FORM OF EXERCISE NOTICE

[To be executed by the Holder to purchase shares of Common Stock under the Warrant]

Ladies and Gentlemen:

(1) The undersigned is the Holder of Warrant No.___ (the “Warrant”) issued by Bellerophon Therapeutics, Inc., a Delaware corporation (the “Company”). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant.

(2) The undersigned hereby exercises its right to purchase ________________Warrant Shares pursuant to the Warrant.

(3) The Holder intends that payment of the Exercise Price shall be made as (check one):

☐Cash Exercise

☐“Cashless Exercise” under Section 10 of the Warrant

(4) If the Holder has elected a Cash Exercise, the Holder shall pay the sum of $____________ in immediately available funds to the Company in accordance with the terms of the Warrant.

(5) Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the terms of the Warrant. The Warrant Shares shall be delivered to the following DWAC Account Number: _______________________

(6) By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under Section 11(a) of the Warrant to which this notice relates.

Dated:

Name of Holder:

By:

Name:

Title:

EX-5.1 3 blph-20230303xex5d1.htm EX-5.1

Exhibit 5.1

919 Third Avenue

New York, NY 10022

(212) 935-3000

mintz.com

March 6, 2023

Bellerophon Therapeutics, Inc.

184 Liberty Corner Road, Suite 302

Warren, NJ 07059

Ladies and Gentlemen:

We have acted as counsel to Bellerophon Therapeutics, Inc., a Delaware corporation (the “Company”), in connection with the preparation and filing with the Securities and Exchange Commission (the “Commission”) of a Prospectus Supplement, dated March 3, 2023, to a Prospectus, dated July 2, 2020 (collectively, the “Prospectus and Prospectus Supplement”), filed pursuant to a Registration Statement on Form S-3, Registration No. 333-239473 (the “Registration Statement”), pursuant to which the Company is offering for sale under the Securities Act of 1933, as amended (the “Securities Act”) 718,474 shares (the “Shares”) of common stock, par value $0.01 per share (the “Common Stock”), and pre-funded warrants to purchase up to 1,781,526 shares of Common Stock (the “Pre-Funded Warrants”) (such shares underlying the Pre-Funded Warrants, the “Warrant Shares”). The Shares, the Pre-Funded Warrants and Warrant Shares are collectively referred to as the “Securities.” The Securities are being sold pursuant to a Subscription Agreement, dated as of March 3, 2023, among the Company and the purchaser named therein (the “Subscription Agreement”), pursuant to which the Company may issue and sell the Securities pursuant to the Registration Statement and the Prospectus and Prospectus Supplement. The form of the Subscription Agreement will be filed as an exhibit to a Current Report on Form 8-K and incorporated by reference into the Registration Statement. This opinion is being rendered in connection with the filing of the Prospectus Supplement with the Commission. All capitalized terms used herein and not otherwise defined shall have the respective meanings given to them in the Registration Statement.

In connection with this opinion, we have examined the Company’s Restated Certificate of Incorporation, as amended, and the Company’s Amended and Restated Bylaws, each as currently in effect, such other records of the corporate proceedings of the Company and certificates of the Company’s officers as we have deemed relevant, as well as the Registration Statement and the exhibits thereto and the Prospectus, the Prospectus Supplement and the Subscription Agreement.

In our examination, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, photostatic or facsimile copies and the authenticity of the originals of such copies.

Based upon the foregoing, and subject to the limitations set forth below, we are of the opinion that (i) the Shares, when sold and issued in accordance with the Subscription Agreement and in the manner contemplated by the Registration Statement and the Prospectus and Prospectus Supplement, will be validly issued, fully paid and nonassessable, (ii) the Pre-Funded Warrants, when duly executed by the Company and delivered to the purchasers thereof against payment therefor as contemplated in the Subscription Agreement, the Registration Statement and the Prospectus and Prospectus Supplement, will be valid and binding obligations of the Company enforceable against the Company in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other laws of general applicability relating to or affecting creditors’ rights and to general equity principles; and (iii) the Warrant Shares, when issued and paid for in accordance with the terms of the Pre-Funded Warrants, will be validly issued, fully paid and nonassessable.

Our opinion is limited to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation. This opinion is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein.

We have relied as to certain matters on information obtained from public officials, officers of the Company, and other sources believed by us to be responsible.

We hereby consent to the filing of this opinion as an exhibit to a Current Report on Form 8-K in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act and to the use of this firm’s name therein and in the Prospectus and Prospectus Supplement under the caption “Legal Matters.” In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.

	Very truly yours,

	/s/ Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

EX-10.1 4 blph-20230303xex10d1.htm EX-10.1

Exhibit 10.1

Subscription Agreement

This Subscription Agreement (this “Agreement”) is entered into as of March 3, 2023 by and between Bellerophon Therapeutics, Inc., a Delaware corporation (the “Company”), and the investor set forth on the signature page hereto (the “Investor”).

Recitals

A.The Company has authorized the sale and issuance hereunder of 718,474 shares (the “Shares”) of Common Stock, par value $0.01 per share (the “Common Stock”) and pre-funded warrants in the form attached hereto as Exhibit A to purchase up to 1,781,526 shares of Common Stock (the “Pre-Funded Warrants”, and together with the Shares, the “Securities”) (the “Offering”).

B. The purchase price of the Shares will be $2.00 per share (the “Common Stock Purchase Price”). The purchase price of each Pre-Funded Warrant will be $1.99 (the “Pre-Funded Warrant Purchase Price” and together with the Common Stock Purchase Price, the “Purchase Price”)) and the exercise price of each Pre-Funded Warrant will be $0.01 per share.

C.The closing of the purchase and sale of the Securities (the “Closing”) shall occur on the second business day following the date of this Agreement.

Agreement

In consideration of the foregoing, the Company and the Investor hereby agree as follows:

1.The Company hereby agrees to sell to the Investor, and the Investor hereby agrees to purchase from the Company the Securities, on the terms set forth herein. The offering and sale of the Securities is being made pursuant to an effective Registration Statement on Form S-3 (Registration No. 333-239473).

2.The Company represents and warrants to the Investor that:

a.The execution, delivery and performance by the Company of this Agreement has been duly authorized by all necessary action on the part of the Company. This Agreement has been duly executed and delivered by the Company and is the legal, valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, receivership, conservatorship, reorganization, liquidation, moratorium, or similar events affecting the Company or its assets, or by general principles of equity.

b.No authorization, approval or other action by, and no notice to or filing with, any governmental, regulatory or legal authority or any other person is required for the due execution, delivery and performance by the Company of this Agreement or the consummation of the transactions contemplated hereby. The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby do not and will not result in any breach, violation or contravention of (1) the Company’s Amended and Restated Certificate of Incorporation or the Company’s Amended and Restated Bylaws, (2) any law of any governmental entity applicable to the Company, (3) any order, writ, injunction, judgment, decree or award of any court, arbitrator, or governmental or regulatory authority to which the Company or any of its properties is subject or (4) any contract, agreement, license or other instrument or agreement to which the Company is a party or by which any of its properties is bound, in each case except for breaches, violations and contraventions, if any, as would not, individually or in the aggregate, have a material adverse effect on the financial condition, results of operations, business, properties or assets of the Company.

c.Upon issuance to the Investor against receipt of the Purchase Price as contemplated by this Agreement, (a) the Shares will be duly authorized and validly issued, fully paid and non-assessable, and (b) upon exercise of the Pre-Funded Warrants, the underlying shares will be duly authorized and validly issued, fully paid and non-assessable.

3.At Closing, (a) the Company shall issue the Shares to the Investor via electronic book-entry at The Depository Trust Company (“DTC”), registered in the Investor’s name and address as set forth below, and released by Computershare Trust Company, N.A., the Company’s transfer agent, and (b) the Investor shall remit by wire transfer the amount of funds equal to the Purchase Price for the Securities being purchased at Closing by the Investor to the following account:

Account number:

Routing number ACH/EFT

Routing number DOM. WIRES

SWIFT Code INTL WIRES

Account Name:

Account Address:

Upon receipt of the Purchase Price, the Company shall promptly (and in any event within 2 business days) deliver the original Pre-Funded Warrants to the Company via overnight delivery.

4.This Agreement will be governed by, and construed in accordance with, the internal laws of the State of Delaware, without giving effect to the principles of conflicts of law that would require the application of the laws of any other jurisdiction. This Agreement may not be modified or amended except pursuant to an instrument in writing signed by the Company and the Investor.

5.The Company and the Investor agree that the Company shall issue a press release announcing the Offering and disclosing all material terms and conditions of the Offering prior to the opening of the financial markets in New York City on the business day after the date hereof at the latest. The Company shall not disclose the identity of the Investor in the press release without the Investor’s prior written consent.

***

The parties hereto have executed this Agreement as of the date first set forth above.



		INVESTOR

		Tang Capital Partners, LP
		By:	Tang Capital Management, LLC By: /s/ Kevin C. Tang
			Kevin C. Tang President

		Address:	4747 Executive Drive

			Suite 210

			San Diego, CA 92121


Agreed and Accepted
This day of March 3, 2023

Bellerophon Therapeutics, Inc.


By:	/s/ Peter Fernandes

Print Name:	Peter Fernandes

Title:	Chief Executive Officer

Exhibit A
Form of Pre-Funded Warrant

Bellerophon Therapeutics, Inc.
FORM OF WARRANT TO PURCHASE COMMON STOCK

Number of Shares: 1,781,526

Warrant No. [ ]

Original Issue Date: March [ ], 2023

1. Definitions. For purposes of this Warrant, the following terms shall have the following meanings:

(b) “Commission” means the United States Securities and Exchange Commission.

(e) “Registration Statement” means the Company’s Registration Statement on Form S-3 (Registration No. 333-239473).

(f) “Securities Act” means the Securities Act of 1933, as amended.

(h) “Transfer Agent” means Computershare Trust Company, N.A., the Company’s transfer agent and registrar for the Common Stock, and any successor appointed in such capacity.

4. Exercise and Duration of Warrants.

(a) All or any part of this Warrant shall be exercisable by the registered Holder in any manner permitted by this Warrant at any time and from time to time on or after the Original Issue Date.

5. Delivery of Warrant Shares.

9. Certain Adjustments. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to time as set forth in this Section 9.

(e) Calculations. All calculations under this Section 9 shall be made to the nearest one-hundredth of one cent or the nearest share, as applicable.

X = Y [(A-B)/A]

where:

“X” equals the number of Warrant Shares to be issued to the Holder;

“Y” equals the total number of Warrant Shares with respect to which this Warrant is then being exercised;

“A” equals the Closing Sale Price per share of Common Stock as of the Trading Day on the date immediately preceding the Exercise Date; and

“B” equals the Exercise Price per Warrant Share then in effect on the Exercise Date.

In no event will the exercise of this Warrant be settled in cash.

11. Limitations on Exercise.

If to the Company:

Bellerophon Therapeutics, Inc.

184 Liberty Corner Road, Suite 302

Warren, New Jersey 07059

Attention: Nicholas Laccona, Principal Financial Officer and Principal Accounting Officer

e-mail: nicholas.laccona@bellerophon.com

If to the Holder, to its address or e-mail address set forth herein or on the books and records of the Company.

15. Miscellaneous.

(e) Acceptance. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein.

(g) Headings. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above.

Bellerophon Therapeutics, Inc.

By:

Name:

Title:

SCHEDULE 1

FORM OF EXERCISE NOTICE

[To be executed by the Holder to purchase shares of Common Stock under the Warrant]

Ladies and Gentlemen:

(2) The undersigned hereby exercises its right to purchase ________________Warrant Shares pursuant to the Warrant.

(3) The Holder intends that payment of the Exercise Price shall be made as (check one):

☐Cash Exercise

☐“Cashless Exercise” under Section 10 of the Warrant

(4) If the Holder has elected a Cash Exercise, the Holder shall pay the sum of $____________ in immediately available funds to the Company in accordance with the terms of the Warrant.

Dated:

Name of Holder:

By:

Name:

Title:

GRAPHIC 5 blph-20230303xex5d1001.jpg GRAPHIC begin 644 blph-20230303xex5d1001.jpg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end GRAPHIC 6 blph-20230303xex5d1002.jpg GRAPHIC begin 644 blph-20230303xex5d1002.jpg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end EX-101.SCH 7 blph-20230303.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 8 blph-20230303_lab.xml EX-101.LAB Document and Entity Information [Abstract] Document Type Document Period End Date Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity Emerging Growth Company Entity Central Index Key Amendment Flag EX-101.PRE 9 blph-20230303_pre.xml EX-101.PRE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	Mar. 03, 2023
Document and Entity Information [Abstract]
Document Type	8-K
Document Period End Date	Mar. 03, 2023
Entity File Number	001-36845
Entity Registrant Name	Bellerophon Therapeutics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-3116175
Entity Address, Address Line One	184 Liberty Corner Road, Suite 302
Entity Address, City or Town	Warren
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07059
City Area Code	908
Local Phone Number	574-4770
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.01 par value per share
Trading Symbol	BLPH
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false
Entity Central Index Key	0001600132
Amendment Flag	false

XML 11 blph-20230303x8k_htm.xml IDEA: XBRL DOCUMENT 0001600132 2023-03-03 2023-03-03 0001600132 false NASDAQ 8-K 2023-03-03 Bellerophon Therapeutics, Inc. DE 001-36845 47-3116175 184 Liberty Corner Road, Suite 302 Warren NJ 07059 908 574-4770 false false false false Common Stock, $0.01 par value per share BLPH false EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 22 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.bellerophon.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName - blph-20230303x8k.htm 9 blph-20230303x8k.htm blph-20230303.xsd blph-20230303_lab.xml blph-20230303_pre.xml blph-20230303xex10d1.htm blph-20230303xex4d1.htm blph-20230303xex5d1.htm http://xbrl.sec.gov/dei/2022 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "blph-20230303x8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "blph-20230303x8k.htm" ] }, "labelLink": { "local": [ "blph-20230303_lab.xml" ] }, "presentationLink": { "local": [ "blph-20230303_pre.xml" ] }, "schema": { "local": [ "blph-20230303.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "blph", "nsuri": "http://www.bellerophon.com/20230303", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "blph-20230303x8k.htm", "contextRef": "Duration_3_3_2023_To_3_3_2023_NhcjE3buhkux2INPjWi2OQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.bellerophon.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "blph-20230303x8k.htm", "contextRef": "Duration_3_3_2023_To_3_3_2023_NhcjE3buhkux2INPjWi2OQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bellerophon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bellerophon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bellerophon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bellerophon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bellerophon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bellerophon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bellerophon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bellerophon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bellerophon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bellerophon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bellerophon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bellerophon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bellerophon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bellerophon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bellerophon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bellerophon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bellerophon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bellerophon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bellerophon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bellerophon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bellerophon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.bellerophon.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 19 0001600132-23-000018-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001600132-23-000018-xbrl.zip M4$L#!!0 ( -A#9E8CHB0<=@, %D, 1 8FQP:"TR,#(S,#,P,RYX MK5;1C').E2R74D1$%DXL M@;\ 86,4FU6&?I*JN*%S7'$#61&_*LR= 4@6IS87+<(.#-D5>@I&6CNN)I%4 M"]@H2>.G^[MOSJ,GYY0UY/5,\4A3$BWD[Q@ ZRWS1*C. N.R(<^QGCG=&FB1 MM3*A>2ZIWJ@IY)* M*;B,S_WI\&C+QIH/NIC$3W=,_/1,@1G1_0#8:J!5 9"6,&G*^ =OI M-FK0^5D,Z(Z57A,M-0X''4F$A6?0AIY.UV39;]4BG01WI>O+G)Z=G<4.;9PR MTB\*0/>J#5Q-C[3H@B[LF!A)EZU'7-,:-Z94 W8 :6UP0-O[OF8O]W7(A#98 M$+K; 6RD.EW^C)?+ P=674Y1%5E?AV4)%-10H=F,T]#2J,(&)K\.,SOYZP%D M5*<>+8\ QQ9V>F&2AEFZ'5VEHN20XFR9VZJ:ERMJ=CR.L/-MNY"=N=1N0CIO M7VP[>ECO7#K9S"46P$L%(?=:P4)(XU+GUOQJ63(QE_42+-IVF%KOCY P9!^^ M/]R.UM(=]*9^P_K_[T7^41AFGF]!715NWP QR/)!S,:/=Y33.1/,N4\@7PD* MD1?8?<0B1QLUM"-W'G"T(H_S_G.8^[ MS5:OM)O2M20<32J#1.^7W]#&ULU9OA;^(V M&,:_3]K_\(Y]V:0+:>AMNJ*VIY;K3=7H%1U,.VV:3B$Q8"VQD6,*_/>SDS@E MJ1VXT$7F2R_E??+X>;.((GQ!),R57'ZYYU )& AIC,KSJKQ/&3 M ./.^^OOO[O\P7&^W'X>0DB#58P(AX AGZ,0UI@O8$*72Y_ V(,1Q'<,AS. M$8!WUNUUS[IOP7%RCUL_$>=0 JE9K^L5E4'N1TD?SMU?W=Y9[QR\7O_MN[[W M#D8/A?!!Y)OAO=]?G7?TD*.C.Z9,;(BS?ZIX\<.2!G+8?Q2]?!U0P?#--./,#KIS2_%<=75U. MQT%S[!:II=D-*T?W6: &$X=[9B)7N $59"VYDSJJTV>,QOJHV7!44_P:3:/F MO90:82BA*Y8"?_B;NIO?--=%1J&02PHBSA_C;PA]_4&M-CX)X8YPS+=P3V:4 MQ>G_1OA;C?3/99;H_\1,A9D(1TWGE;+%D.D:48SMUBQ%3!OQ:,*D6XL0C1## M-+PCX0=QU:MILJH[ :RTK57Y*HDL!TV?]6CB,ENQK(4@C5N +UM!/^((?5K% M4\0T/6LD%B-G:DC15JU;"IHQ9E/&\DNE=(3,LC6Z/J,YEM=DPC_YL6YE,\BL MITS?6)FTLL9JV@Q1CR3NV16D;6O4W8O;5K:D+-T6CKE83@=T13C;#FAHAG#? M6=8S>5#;941K3[&:V,.2'PEP:9 WD X#E$$^%,BQ6J-ZXF_N0[%5P#.RC[MWWAOPE#,6M)_L\0$^09)T.OM1[2 MFA;+@&J$5L-9E_=(,'//-^H I#L\DO96T7S@@3A\9!.Z)ONFH:0\%2A?MJ=% M\EEV"D!JTKX6CM):7MBE>=LHIKN*1S9B] F3P+P_-QME$)\*I-HFM8B6E*< J#[P:^&9N8.P;^NV M2"[:-PSY!APK98L!U#52?,VW4[,4,FW$IEBE5V+IUA9%\LO\:+2@Q/PQN$9B M,4VFAA11U;JE5!EC-B4K-834L;V[X3\9YAR1 8WC%D)E#ZMX^FO=)LD+LFP#5G7(ZF!H;-L#Z0G\:R)ICOQJXV1!M\SM& MP4KL'[9>;SK!/-+=YFHD%O-I:JBX>E?JEO)GC-F4M]0%Z R\WD_3GT'YMX#8 MA/GR$?_Q-IY27:O5NL5P:5M19)6*EF*ES]B8JG2?1YY*([D7\#F+^5G7_\'4$L#!!0 ( -A#9E9Y MG]T'=00 /DE 5 8FQP:"TR,#(S,#,P,U]P&ULU5I=C^(V%'VO MU/_@IL_Y9F8 #;MBV-D*[;"#!JJN^K(RB0&KCATY9H!_7SO$%$("H6K#1B,- M(3Z^/O<?RXB0AX1SS!C/8,UW(,@&C 0DP7/6.5F# ),#8^?OCYI\=? M3//;T]L+"%FPBA 5(. ("A2"-19+,&5Q#"D8(")XW"! ' =R[,30P*9*$VZFP3WC*40<=>VU^NUM?8MQA\FZ,&8F7IK+ D7\JDU\_95-$?_9I^$P%%MLAG3,>I3H:0,7__6UXQ&6& M"$&GCI0)GNIP?++]P&3ZT9_E@@. Z$C$2C5ZAFY-OO_Y*'5FLJ( M.1KYYN_W?MOU'QS_OM-V.K[OWK4.R!W.ASX_)@IYH&/+PY,I*8R?I*K]1G! MCW#-4OXR]TP(HZ%5]A M5#3KBV!-TKX"\TS_UBWT'\I-*8\93]6:2-'0@*VHX-L!"\OM.-OK.,>6[SYT M?EAWKD\D,^ON%F9-X688RF3E)GVW9[ZP6I7@FV30-2EDUMS?PII^&$K=DNQ# M[GJ16VI+ ;9)EE2EG]GQ<$,[!O+PE4_9FEXRXQ]D ZVX0#XSHGU#(]*E]96/ M.7O'NYKYK!LY> ,MJ9)!YDOGAKZ,62(@^1/'9R_W1> &>G*9ORX G7HM4;_? M/D>PQ(3#YF;(?I&Q%KKF4EO=:R3C):/E=5X>T@S!*['6HM=<7/_!L1"(#E@4 MK6BVBTL*E"_$-4/^ZM2U!S47VQ-&<( %IHN1O"YQK 8\,> 4U SU*_+6TM=< M9X\Y4O,"R5U >O-1W:OFK_-YX>I3#FZ&%5?RUY;47$WG6 Z39(7X5<:<=&FD M/=6RT";57%=/4+"2R^K6]693]42G:,'*08[IWTGZ/^)]P4JLM>@U5\]3#M4C MZLDVFK&B2\11>S/DODQ9:UUS@:SGP?,F6$*Z0"4WP(M@S5"^,G-MP$TJX><( M\86<(+]QMA9+N3S&D&Y+2^%"=#/LN#8!_2BNYF)X1W,@,^20#.6E:?,%E?N1 MPS7)B2K4M0?8M2#DQK769R&B4JU006W[ MA35)!D@)">:BT%__[CU)("!XJRA:VG.LD,G,[/N>/7O/[/QW-+#(-7,]T[$_ M_2L)XK^$V;ICF';WT[_GK8-TX=__[OX/@3_\!R$[_Y=.$_/;WMD),1P]&##; M)[K+J,\,HLFRY20TW33H[E M1):5"S"O:4_PST[/![P";FVO9##STU;/]X>E3&:DN9;@,5WH.M<9>(!0R%MA MPTFCFYL;X481'+>;D8K%8F:$G46-2I9I]V=:\BZQK2R*2@8?:X#,N/GH5ON9 MGO%IW%2SAKV9EAJS+.8ZPYYC"[HSX!@7X>^D;QC9\&=ABR:2S80/)TT70@<- MI9I=A68UY^V=,?V00K3_G@(J(L^?=KRVV-N^*MI&,SFOT*#4U 0KJF'LQKY9XB5_<#E2&XK\!=YJMUR MIK^?]O2?544+>OU@)-=.&S\O3;G^=8O8=(!C,[-4M0&(<06 =*E5LPTV.F;C M+6(:G[9:>OOGQ9=1_NC@JWY^W!%'.;EW>N$97]MR6]K:%8'?)WCX?!Y=?"]6^7>[5NM K3+-#+8^]X R; M3 ]<0&EUI/>HW66G\"2FFEFE@V V9D+1H5YNSNH;TH>%W>8.N'ZI]3CPH+J)QVK&&'D&5O18^3K M3UN>.1A:* 69V3["X9)C\(^>$[C\$Y>O4H0N#M23T!5WQ#CSQ9], S]W3.82 M/B&V4%=5:L>SO#?_\F[\U6SO0T"G8\2?0 VX_CZ8P%V<9UK$_^+WIL\FTS26 M-(V?Q)_C03(SB(JQ.D%C)B'EMS3"@([2-Z8!QE\2Q;\_#JF!_D/:8AV_I IJ M?OJ5:W9[D^\F M-2[]VS('S".G[(:<.0-J_YL*OX%_/0"\\^]'WMHS?S'H&A1>/%$8UG<&)2GQ M%2I%_(SX25/+[-HE'0C&W/ ;TT9ZEK 3S7$!4=,^1L1S+-,@?XG\3_R<:UD! M7IA['"IA[(G@_]GP7X310\7C3@:[!M(.=W4,VLY) M>4G.915#-%041_IH^:;;*K6IS)Z.%0+\I M$)K5ROE9K56K-DGY=)]4OU6.RJ>'55*I?_E2:S9K]=/7A@OY;3%@LY!J;/TO"-SDI# MEZ5O7#J$-NA+X6Q=-G1NG M+5CNE@R8Q@!Z[!ET/(:Y,'N1;FEPWZ\:>H0))7.3RQYE#:DLBD&_TSY(7]:^ M5(Z[6[M?J*OWB)(B.(\5:I/E5'@IP9>?HM16O>0]8UW3PT"%/UVA<7JU+O36 MK\_M[*_^9;4;&![MR.WCK_<8A;UI=(>T>@S8F06^J7LI4K-U88WLQ0.=8)D_ MW:Z.*.@/1!"*X11EA'JD.60Z+K@,8MJDTH,U$W,_/+_!^&WVC3SP?$[56%&5 MVY05Q;::5SMM6E!HFTH&U8U.+J=0)?+ :1Q7\#RW+1W:Q6]B[N#FJO U^UUV M+KIMN2W.MSSNGY[XE8Y9%:\&E:+$CGY\,Q0,E,CS+7]^4\8V'@BPO _<] *=C-;%UQ0ELWQU7'(-- O/I8O'"^)RNG)\?MB^RFI?+[F5[Y;;$#>A=_M0^ ML^@->-I+/:?U$ML$*7\&GF]VQH^@Y5UX"-=WMW].UG)K+^'KQ.7S3'Q@6@QZ MUY@[X5@O=]RT@M;%854NNZ8Q_DI_-6Z^ L?*]U!*%*6TDBNHV0W+;EAV=2S; MHJ-:M-6E\^[F^/>S7"B/-+6=$YD>=/KTF&CI73=YB8.PVYU'Y;WY'/@FIYA\J <+HUGS.&' M![#Y%$EK*>O*X@C!TZ/'#\7&&Y'X*7ZV*\Y@8'J8#[6CN22SBT:%A%*Y880_ MB1%J9TU2'0PM9\S#6GYLLXMJ=5]:&.K[-;SL[@>TJ?6OE/'G@5$1?XE[Y42H[_T& M\-3"H^UY(@4E,:(#HW0LYR:F>_R9;P25-)?1?OH&,'=O6DND@/A4XJ94\QPK M\-DH(I>)SECU0O"LF&XS/.B M?TY,FTF)SO[\MPD0HJIOH#]L>DXK@VK'?. M'&JD2#,P81&DB/+")>)=78;^T(JS?&804H%?ZV[+N;$3Z,A??^\ _/US\;#Y MLUL=-+6*FNW>EU8%;S+[T2"GR$K ?72D-L('7\#6W0:T-'E9P 0I)]_=5O>D M)_VJ4O?7#^^'&!V==\\KHXJ8&UW]DGK=[D."LGDQ6_S=>-9ZV)WG#VE%*,?P5<,% MG6 .J46J(Z8'Z&^0>@<6KLQ;SQC&@V*Q+Q&P>&.B/,\#(&D$1>VUXA)O)O?T M =F+T_0HA$#*?_2(SRR&.6&,V#P@F"(@9U: 7$$H./N@2 V6R&*\2Y=MK]A[ M0H>I#'.::E[N'0RONYURQ_GEG&?!UD4"X_VESZLQE^: GCB M@-@VD!K)/1,.I%Y-*Z/AMVI'# :Y7)7'%V7UK(CR_ M;W^0AP_ >X7E1)A1Z)+H8V2)0#HZF$EH=YE!FNBEDA/J^>2,Y_M^>'\XO=/E MJO28WN=YW70(_OW0-7$'2G-&1&.6(PM#Y+*2/20>F#KK%]$#1^ QZ M-C![W#,'@>53FSF!9XV)!V+D=<;\]>@%1P,RTG@W"Q^XTV3/ /IQ";7'\;.. M8\$,\#U<>)BX]^&1[1US-B* OY=,<.=,'<#Q&%9A[I)#!NM)<#1J-O0>A!MH M94$60J@^E%X*O3-4CZMPP]+CM&8Y>C_>A\BMQ@&>7\=ICF-I%/#J XF3:NO2 M-7T@)6XS!7:TE> E=%>S,KA@QX>]H_//--0=!HI^LWBW(&\EVM?'JA?#\_9P7K^P&SZ$7N.,X5G6G9 MZE_N?^ZG@T&_?E2VBJ/<<%1TNE%6WDS+X:!G]KZKEU0T?SFF>WS^971U7OXC MRH-4\;U4(*S-IL?K 2?EA&)V0\]W0T^E*(C*>Z'G8_=\7D4Q/?N&3PM/*PO+ MZ?4>T2WJ>6O(XK]5E["$/4(SM'S3]FUIN-\I3[@302V7\IV)T-?>]CZLKR)\ M,USR:GIS95P2GP; M0B+5SF.36YZ)GPS76)LU.ZJ4R?BLP8E6>/*?9(P$>Q? MMH<_"X=!OWG2R1ZE!^U"\_/7*)OYKCTM7,D#*9N^H_=3Y#^B($ID2%UR3:V MD2$>S==[>EGFFM5[+2>-HP\0K9^(W:?WNXIM6CX5I"DG<8GPT;8[2(=)*=Y[S M>GN IX)X=^@S3M.DGD&O0DZ_/\6$5.@0-VS)%^KVF3^;S?C.\X*6!21KMH$1 M8$:T,='YECP\[H.SPW@AZ-Q6N>D1 (*!,NFB)]UUG1N_AX'D(6Z?4X\8K&/: MX9E)B7U/,4MNG^$V/;I-(=O8,/^1[WW&C6$L<+Z&>.P2YE(D0M*REI8? V/49B28J5F926*VG=44UE;5(FT75*JW-;'(Q(^WJ^?G91SD;G9,^V M5/>,2_=[@[9$,ZA[_NPW@[>)6DVA\$A79<75,;=+8O!XX-L! MZ_4,43VX0&E* 76#_M=$?U$6I T)5EX<-H\P59"S+ZNDHA'?*)F6Q38>&LEX MIH3Z5]%O;YMRZW,RV-(\D+".IQJYOH?<\ZV$CN]DO5YF58L-KHX&(A/K;9GF M@UI^#_?!I4OP/8;7JXE7.8S2XH@CYE]7@\8AOE#B/TN"Y=Z7! MWSCEEHC5/31ZK!Y\3;WWIQ"HUKDCQH,57@L#1N:MLHH>]0BSF([W\-D.3\0+ M/,9;P52BX@V\28TC@81W"Z$]YF-98QP<+PGDE1DVP E/7 8B#.]U3)O:.J91 M4UW'@SFQ,=Y]9E#7\,*R#>/.+$!EF\YF 28#1\(=2OZ//M)HS2>5?^E)/> & MJ-G[G19=X92XX>GV]4]K28LENRT3)TI:HNX?.\F9VP.?,./D%'EF>:3*%_A] MRZ8\A5Q\D@/QO_\SZK)T:%%HQV=N MB5HW=.S%5DT2Q-S?$?N4)JR"=S$2?FL:F?Z*8#WJ*C9)%)3L_%UL\9?/>QE; M%,)65$W.YV6Y7=!UHZVJDMXNB(RVJ4R+142Q7(QO,%@1%\]+\ZWZSIK/HF)$ M0+TDD"J>"(VEB ZA)*Y*(ONX!V+R0P;*79?Q9/OGW%98-,VD=>Z^XX-LHY%$7I?%C]&ZEW^2/GX@? N2[_IP3'B!YNFN M.>1VG<8HB(TYP5M*33_ IX MT[YFGN^XJ1EC'2;;X)"5>',)^^'EGB:68$!' MX/?!E'&KB28S_PW397SOIP/8 [<@.?%Z].5DYMOF!YP2[4+OW>@ZGKQ42*EY M-4P%\6;>;_*O)F]'KD,"';PL7@^S3+Q[LDQPURM&YR0K9=(WPK=MPO2P!+\3 M<'?IAKKH6LW.">LZ#L+GE]'S22> +< J.#;@> 5#_"BE\@4IE95S,7@ 0W)\ M 6E/0CB!8H!?C:%)XIC'4>/^7(]0'S _=/'VXRE0T-]_9$$4IU^%72Z8YFS_ MV)L])5O8+_:&I^SRWFYWD9ID90&6/(9]\CDF9C/3'7J7$<4F$!,+3PFA,9TF MK[(1:25$ M-JS1]I*>_P0W\;[K%)8IK: ]7P(PGRV4K[/JWGGM9)\T.%\K 'Q@C+G ()%@ M[=7'7O1HLQ^_[T95V?$IQIR-P1@Q+R1;W&/8$^YRQYVG"!#7< : )2-%#"< MYS^M@3,!G\ WT9GF\#U)UP'M"O/8J#@''!X"!T?%2\]X86!OHX?%I>9ZCFY-[V!/-.J;F@I'V,./1 MX AAH#"G&*8!;& KGDJAP(A0C&778U.QV_$UC I,P.49(* 8L1.W1N MN);^I^M_+(I_I\CV,!WJ1>@&)?##1$A![@8X)>"AH0.\A"THB59I /"7BT:9 M#!CU NP0EJ,49*H+$^R-B1;=$1\M2KW \B-Y#.DJAW2/.344-\ZIT>5LX(VC MQT@,ZE,<;& :_,+A]92X9M+B3IP.'AZG8&Z)'H QXLB<:,JPZB\5VQ3,G4"V MFYAK#S&:D+Y4HA/HUS##JD&450L8!I4;SGI@3WE]>NJ"-V0]6^F%\8'(4@T!.G;!"^L8U49TBGZ,H<"&G^06]T8B(>!;=HZ+)T\?A*+P:+?N=$!38AI<\ J*:(%/D<0, D;Z=&!81*' M)84B$,:2^(E&/K@*>&!+3@)"C+W('J&>@A&@#W03(B\IXO-5N_TSP88G:X]8 M,% _:RP\I>QP(L%-N9N60ME/%) MW&UZT/RLRUVMQ.XL: U8AX)"L":]0N// :AI.<>7,2+9#L^G=P2B*$I:5HIJ M7OF02JPGH#_D!HNBT0CY"U=JO"/H5@[[287*D/!U*@82P2BBB0@ [& (K@E? MU#VG+7@9C%DN,&:IF-J/\$-!PX9>/%WZP7/L925GH@^#Q.71R]T-"[8>* M/J'^5XN!AYHY8-N0&RCF__5,S03<1J?M(0HP&.%")XHQ,T, M/_,'&-E!Z PV'2-29FB')@9J^22N FI-KHQ$]8G'X[OHT&EH>($ 6'N?T&9\ MJJ$G@OO0BY790O#454&W2)G^!FAE8);AY& E9PC.;SCP%W#H?J7("6@).P6L MVX.?!\P%QS5%#BWGVNN';G##&3(G11I"14B%TABM$+ _"];L&(R+^X_-8A@< MH&$YX*WUWIP[D)HB.-)1]^!T2H6L(#VGAK\GUIL,53TJ$+DL-)?<'U56NN\T MDZH>@2FKD1H3)UI,?L'H:;XH*$N"IV&8DR1^7^?PZ4LHWU756L27UQ8-)G8* M3+8>F[&S$SLR M7"EXJ]$(\].:7(X>#QL>8?) M>ZR+BUAY[79E7^"^$*&XE'?>-Z>\)M8+JI#-;T1VC6X-B93H;,K!G3D%SUW5 M6;R%E+L*\F(_&I;K3[E:X#ZQ?T$:R\,5'*X0"=C3R+FB\M/'$7A_NMI<4&WY M5,:^-U/F!?B SE3'@O/L4MTO1>O>F5R5?ZX"Q_]X[W!ALX];I.=B-KMF#7M\ MPT&$OR,V4@U)Z/F#N_(G'PC0LI+:R6F"JB!-&):^=:%\_J+O6:E\#"^^W#E2 M[Y@[#Y8&RA8R[=,4S?O6)=F7HU9VHTN>V87>,."C&+#^6R'G)ZJ4:>7!'Z%/ M)/'EZ(G[.AN-LH3;_E!U\I+\MWCW+\4S,_@.'2J:V<1:+50K=.#8W?NR;.,- MNTF6)3&C2[:GZ4P>$)WZ@8NY,EW&,QY=YCM/558;_V>%["(K&W6U<8!>DP,K MCHWI?D]T@,AV>*-;N/&?V/?^\%:UC22J&RE<2RFL8-R?-,"F@2WT&8H@9F;M M8P8NS^KBUZM1/S*T-7Y9"/FV=W:RVNL='WZ,US/NC+_E7?VW562X2=GYG90= M99.RLPXI.X_9C/S]=)V+0PPZP3"TZ6\' =&6= M!ECHPG,6)Y4KO*0..Q$UP+5C@&6;O#L:^#W'Q5HG MX5G3B1YP6B,?*FW1L1,\]_F-JBK<<75U5HBU&O_M!=(4WM?A=0\A@)!=GMNU MP?\+X#\O;?#_BOC/"?*& *LBP&/V8^XT!:_AFOW&*67/H'S?*\3+U=T[A?@N M!?,&0=Z(]!\FTK"6P"\_;N.H?DI: M1]6S MPAI\92/>;U&\;QNQ<>F)VXF1'+]B&AC08'D-RP%R; O:\MR#; MZ\7=&WE^GQ#?(>FO79?S2#''FUY+RP3]SCJO'9>WT#US%/ /P&5X,3!D,2YH=&WM?0E3&^F9 M\%_I;[+9H"TA<_G"DZE/!GE,@H$%>1Q7:BO5DEZA'K>ZE3Y@M+]^G^N]^I# M8P/V,)78EM3]GL]]_OC_-C<'R2Q,QFH2O!V^.PXFZ;B*>R+(KCX'4632Y5$+SL;>_UMGHOGVUN_O0C#'4@[Z3)?K#[Y-F3 MG:V=W6![9W_OQ?[V=G#V+MAX/SSHT,.'IP?#CV<#GO3L_>OCHX/@A\TG3S[L M'CQY#DQ^"'V9%L=A_\N3Z^KIWO=M+L\LG MP_,GLV(>[SV)TS17O4DQ^>&G'_$;^%.%DY]^G*LB#,:S,,M5\=>^6WS.IH4L_WMK:T_OUJ$DTF47&[&:EKL/^V]>&&_RJ++F?DNY:WM9RH. MB^A*X=C.J.-8A=G^*"UFKZH3-+VYT.]-TZ38G(;S*%[N_V48S54>G*CKX#R= MA\E?NOP-_)VK+)K^Y14]G4?_JV!HV%ZA?BLVPSBZA,%QK:]X__NR]9$W";^V M#3_1QVM%NQNE\02>'?PVBT91$6QO];9_?#*"8UM\A46. 6!5YJPRP/]O[_ _ M;KGD'_$[_?@DRA=QN-R/DCA*U.8H3L>?7EU%.6PJCHKE_BR:3%3RBJ^%Y_K/ M/[W8V=I]]>,3' =FSGZBC?LK<*>DC10(Y-,TF^^7BX7*QF&.]WE1CO)Q%BWP MGH/^9:84XN;7.\A?R[R(IDO^*DI@:\7^[K-%L>)HA[,H#YK7&6P4^",>R,[6 MJQ4G\,-/WM[HA>U7G0!>IIL%DA(E11J$>9!.@W=A-IX%N]V R,MH&83))!BI MXEJI)'BMXEAEZ6(&"QG.5!8N5%E$X[P;'"7C7C<(@T- E^LP4\$XS19I%M*: M8:7J1@L]2.= "9?N,KNT !P@2JY47J19 #0F@,L$R@ECXR\YG&Y8E##K(@3* M"0M3L)\;SWHD [O3]AX&+MT0DL_5."K".']0L+L>U9WQD9![@^,8C/@T366X MW[4M_H@#[2=PDF'L$2KY"K"FIZD,_P4 'PB !C- EK L9FD&HS)XYF&L"%:C M/"^1YQ,6V&>&=";#'>TR-3F%'<" DN8 006.6 C[1I!,0B+ M(AS/X%?!/#B<'TL]&5WJ1(V%&&R.TSC-]O^T1?^]JOZ*T+%/AX;_JOW,MY:G M<>3RO_Z/3\J? IAX40+Q I0(R@5^W.X^?['=?;KS3)]ZY>1N?CQG< )O^ 0^ MR DXIR0T*KU4,%[&0AV.S'?7#6Y\UVI<9B!V5.[[QJL\G4X!X)-+CY %CP3A M"Q&$UWB658I@0&Z118#S &'VY@$20)X? 5KN]+:V?B]:!F=ZJC.X\+PB0DHW+P0$):-%/VU(.,K"8OT5&1Z<1]!X<=-#N0E"URYX#I,X6%Q#\%E4J,U\$8X1%:]!,X-IMGM- MHJMS<#E*23DH=?BW>[S=U0>>>\+6-$OGWF7Y>-O5^ ; /<\=[0U'C!+F7:F( M+JOP'W!PI/"9>3@ABH%R=H%+"9- P0!C--0$Y^HRR@N!JHL"4)C49?CP!H75 MB\W=8,-[YB3M!;N[NYL[NR_WGN^BZE>U/OV1@6BG"8@R!3I!KE 1P LS6D$% MC.!#6.S?[7DZ=.>+'^CGG%_HGA]()>,2@:X;3%0,T)HQ:0-JC72;U,;1TD.F M&OLAY7.$YIA)&2]=-131$W Y46-@9R$./6;2RO@':F*AT4I&1^1;,38O%T;& M-9XJ;89!\*M8789Q%Y71B%\:P?$0FQ_!Z7N$7K^M$MCY6(4C5)\OPRC) M"^]W4#3#,2B $SH<$B0CA#0D)EU8X5@!3X%5YR6(=V8P,B "H5BB9!='\ZC@ M=8_"Y%-6+HKQL@LC@R)YI1+\=P9GAKO+9]&B2YQ)953#'+53N()R#J0.I$>8+0:-7%TQ?C!A$HG"W&I&NPAS((F@)PP'4@*.$#<.XIW'R"\(_ "_)'&>.%TBT11.LI M"_J*[H\F K3-82( _@QO"7%C2E0/1,?R"V&[C(<@6<[G'@J1O,>;S?$!X'1P MVH488D9+9JTW645]6LW_/V?>8$(GSJP!M2O\ /RBC M"9]CG*$-U#"A%E,8R M=D9#92&BC4RVL=UQ3P>%^>WGKV"9L,2)D*5SX#0T]X'* ":CL U(N;'3H;7")QRP"BEH/4>( /B+85:D7\+^9!8889=' .JE0*:Z M!@A"LO-KF8SY0GXM)YA7(%7XS,9>1Z;'&QGC"C1D(/$# M3257%M^09F>EAE;S9/,*8**06-%2J!X_TKJJ40KJ.IX:*_"HU&BJC[C&@(12 MI@$EEDD\8(*?(SK0+K**Z[2,D2S090!!C28E\$TFRLPJPTO8!/ KU06."#)E M"*P$.$Z$I&"";$*)P*EYZS1* )'P=]0I([Y=!GDBXKBC4%:B%G"X@?VEF+89!+.V3(73B89FLI"5X\?J3B]9@#/8.%P M2(1:N"I0'C(V>7LK[08GO7ZOV\B2^O%RK%MBLBIN*W4H;#E%; M@;D;U-Y6[/IJ!KF*_0W__WRGCC%5'*S'8-0B+]#,5MN@%T_C(OJN-4)3>,W7 M"*;QS:<[>\Z>V>2X[2R:_YQE>A&C: M=NZ>+TO]_39 ]S&X>F[7O#AZ'QP<=.=;#_K/7_Q$'9R\>'HS1#XU 2H M_LGP^':[V-WN/=U^"+O02'$"O/S&*/&B]_+Y0UI\G^6/&Z]_J[?U(-;_);CM M0_#:D1:V4LGJ-HB\H.;.%P5H(AMD*F8+$)E'R0@'7^QX7MB\HRU5-!@H.+ < M$-\:M*2*R86$9S*.($,S]B[QV/[Q/#JWTV+VK*O"LP5JE9/-3B3==[6-!2T_ MK#E4K/1="=H$R07O#DUJQJ=7B(U.1XMVZ0U@&,%E=(5,0XPKA+7@_@H2?SZ)R!S7"_[S3]O/MEY5=H]. M!#1@P@',TTDTC3 &']03,1V*+:KBCG1,8G T:/@C%1X H-E_XJH47]?4_]WH MW$^;'),UMS4'"!"(M.GB(08XYKE67F&,!)C-6+ML3EW7-.Q31Z[@ ,8JR+YM MP0FV_QEP-P, '%N%,5VHQ F L09$N(Q/BB,L\8X_IMFGX(!<#ZR=>_$JI!G8 M6!6TOR-\%P+N!1P">P'\C2,\RU886:*)6+-E.>;\Q"3@GY#&UD9C >\20;Y0 M'.2!,3,>M*R(5A$<-(SO_G3H]>$XWW18UHH[^"\_7.NF5_=?3<^O%(T]T>RV MLWQAF>BF"1GL1T,JK;C1#!0@_IU&6%X[I+!P!2W6D$X*5O_Z MP(+Y4^14TA8*UO3':1R'BUSMZW^XF\&UBQT"57,R=B<:S%X\ZSU[1J:7(H/_ M(Z6*@:3"=#L_Z$FNT!LQ#F,!6L R>7GO:6][]\_.P6C3 1W2TYZVMM"_OIS: M[Z=&N1!R4Q-5,<$_LL=-_R$V?F]!-O8G*\FYP?/8%IKJ2Z1L<@48%* M-AE6S&]D/1"/Z7;OZ=.%4YTU@2@W>6UN !]O>5/3_(GP=_5590$![T M01*_?+R_Q(K[WBWB4SKXQZ>P/I;"VNRA:71*\ M;9\)8\VEFUKXO6'.,I63GRGX@R/*'W+3WR!UT-%&GZ7 B;]&!XDL?@N(E0:: M&]_KSO:>[ST/!IP8=J6"PPS^?(3/;PT^[X!["123N_UA@? C]7V$[B\$W0^3 M1E^4H,4$.]M;CZ#["+J/A/D1NO]XT/U "7.8!(>1NDR[P4$_>+FSO;/]",2/ M0/Q(HK]3Z&[<]$T"&I[UMIZV;GI7MKS[]W0?A\1Z_E7M\1-#'BWV\ MV+7JVLXJX?T.J.UR_W==T,YGVQ.^_MXPQNU,80[G&\R33B;8^^$1&!\N,-XE M9=GY@^SS$6B_\B;/LLA4?OE>*>DC%?V& /*.J>CG6&*_KT-XA.BO;:[#'J?? M+W4]F$5JZD2,G4ZGT5AECS#YD&'RD0JJ#_=[ MV]/S=\'IF^!#__R\?S(,AJ?!V?OS@[?]BT%PE)<#$\/?C[U^M*>;L" M?K4MW%,-@NHB3[A^-F )]XO8=]I:WSV&N*FUV!9<:G'J7KK82O&? ?SW/W=Y M1#=987"JJP@?4='/P[!0^Q)8PRO6T34/:]VK<;@;A*:(;N#VNW)[Y3H=-KCC MAW3I&G/#+&Q!,@N++O7!N$Q3TTJFI/*#7I=6+NJK"T!3K\X2+0$1=M%#&)5F M3IDR_4+'GY+T.E:32VQ(PR>MN]\YG4?"'&OC^CU^WP(6JLPN.\JYY5:,(^EF M55)-M=I;5'J2K&Q3RDWB0_B#VFA-'<1R&L:/N6-UCAVKN[I)=)C1 :F6GMYN MEVN[_DKCPPWJ9T5M"VD$O$MY7Z,38;S;4!MKM]HW_-;RWDNY:7P<%M0>U6^' M;9=M&J-4VE\'&V$>A!-,R<>N=G1V .9TWOAW2'VZKJ()%W^^4-QS[Z5T=?56 M-M"34X5PLS+JA)2768:%E#/3@T[O V8RI<6]MN$;43*.RPF7Y%UZI<";7^!V M2-1"[#?X.;G$*N6Z6PRU3UO$@';< ),JZ#8=K'^B2SF&I.EPN.%<%TX: M:)(%EPJ$.YVI&VH-[]\EW=KN!:M;#*EIE/"ZD+OWL/$NXB%(N"JOWG.W<7=< MIIA*J_H_SU6(99.ET?.=UW_%GDYR>?TI-I*T5T9+RPDTSK@OY"0"2EGHQG+F M$W6F@PU)(77]D8I!9]SQ2U,=^4WWJ@R8)'9-OU,!!4#7,IAWUL;W?J,16=O&2F$">!G&*V"6SZ%7PI>"G*"E5[YYN8-1QR2S@ M-L"9?P6XP?<)M7RE4O.YNUT\H(&0@<".<%^[&=O=2%WQ"^Q^[5)*WA7S9RKA MS9M92G%A_&I"K0JYYC?VS\VH0[;I;L4L0[\F=<3/N*H^4)\A/(XSOZ/*X_4W M"-Z 2 )GY>KUK^,T1:GT,CCNG?6P)27U5Z276H<= ;=/B$IS,T0BD\2:"JZD M/TO++ ]&81[Q+4U2.'6J5*Y0., WFG9(^TZ:-Y].*WLW)=CW]K>V@K/>.UB] M7V4="?@--HS[Q2G-R!&O-8Z88>(LLG_<9I"0_ 2GDEM0U-S(=M+4K\SYR.2F ML.SZ%;+$RC7_NTQI?='$N6M_43P 5N?9A']L4A<5F&?%^-6MGPX/Y ;SX.2;2NM3@ER>1BKCCU7>Z05' M(B/5<"$88UE^ZL(P#N-QR1T9Y@Q!ZH;AM/6J'F,5%L/1]A' %Z;$W>C@U!9EL+! M];54[(V9VT&I133 &%P=-LTT4JTFJ"0E4B-8A;UF^7.^B+%=+W\ ?CS2:S78 MJJ'?Z8<<3,I,-XYP&@-KD,4G@/A%Z>2^^,W$\)LV0EWGI9]+N[SFOZXXCO@. MC\%F-;U,67(1BN90SRZ/TG4JZ3=(S5T?(T_"?!+^VZE@B2NZKQ-7YL3/2=\5 M#9TD$\2E^GE76V(VOX=G1@;4B\W=8,-[!LTPN[N[FSN[+_>>[W;N:^=3LW-? MW*SOV/^==/&7N[MTZ=)GY[[V<&GVH+'D,%S6)?YKI3Y1LI8+]:VB$& MG]Q MX=PE_QZJ.$(%DJO)'/NJ5%#D)BO$U4FO(OQX$19E!M]U^1-H!OK?^"#O@5IU M3Q4:?^(@5I?PYPR=^J$1+'PI6\BI=PZC,/F$:\*&2%%1,F&NM;9!YN;T,B:= MG#HY$=.D!NR:S'B]SX7H C>B5C:];]&QMOOH6/NV'6LWI"0SEY*P[:E_6:/_ M7Z1KLO1B9HZ0&;7 )2WW0@[&R\[IJF?9>'&O&)Y M^9YG]W0?L&95X@O2^4_TFML<(C)*&1^^*D"+0TBV(JO&,\TRX<;(\($M!$/ L+!)'60L#0MM*?5. M3._W7&9UO"*)R.ASI:^"9]2*XP8S8NEX1Z9SZ?G&B*"?2]FNB+^@GY?Z'HX4 MRP3LGE&D>FKYQC'5HZ"02W-#-'/3.7;JAG'_''&"B5)SUG2!HQ2R>N,5TBNK M> 9DE: 1IG&)&C[>@+:O:V*G3U$L9,8!(H]I6061(1J56HRP"C<32%(1X=Q8 M]M V[*[61D'^0/<)@![:#.1],I>&V1T1S=TU1+-*'#7S$>IX8;T,H.."PFH: M>-*^'1W64?ZPCV9#HU>RBU&ST'&HC0<^KX-INA9SR'%G_#!3/FB^%S(,Z<:= M+J0E'OIK=.BN<2;Q92[")1$[?:G.YLPRBO WV.!&1%#3Z074\5;8Y,SP5&T' MT*^A;3Z!R[RVOJM%LRL*%SG*"WB(>9#8I.:UG6Z829V!'1\APD[5,Z7(@F$Z M5[8=8IZ:A2.6&=59^*%VJ?8G)ILQ<=PU M*R"+BK:2(04)J9R)%@5(XW>6)G35KA\_$M*;>9#L*#:O.6.-Y,"=-S54"F%% MQ&+C=#H"Z3XTZ@QPG(4:%TW+,;U'A9K-POH;]IP:6,T-T6J1J06YD:6K*5K0 MI8NRW_S4"(U -X$N@B)*34^7WJHU*XQRR_ !&P!LXV!2,C MQQT=EBW"[/TY/?L.;0ZS&MA:U!)&2U15,+%^S](#'-:)-[Q HVU1:)'(Y?2W M=K4W2(SWZ*@<6K2?AXX0XFURM-2(*HX2+THDZGCQ&PS#1NPCUA$613B>411- M<('_(-E6]R?U!6\9YH2&L5(D\7Y5B,H# RRE636CV$8$R]#L4VB<']5AY*[$ MQ*M59?2\77H<*>KZ+2-.M,Q*Y"+\I *72QH."%+J+,:VQ/H]+>&C*S(EC_LX M%&W66S!OWE.--(W;WN+0H0[38>U $A$:F4/E)G#UUV3W$BXX M83++RF! Z :[8H0*Y^A.!KH:B@N''8%CK63=#6=]NC8:R0*J?Q#WS%))M3"( MUA@6Y8LU:*I88 31!H;K .(F@+)72)+1&Y[)Q5RG@>,(R!W>Z%&03M>ZCY%8 MJ-Q0=JT L[B)W]3$S6 ,M"4JF"2&EP#M:$%Q0,X&4'KZC\,!#+(Y<9T>3?;) MK:><6Q&6(TDY0D0I\_THC E1D=XBC!*Q100_5&0.3@$>/.-JL"%D]G!X8/2I M8I:EY>6,II 7@P\PTB0+KX%.\6'8&*(@7X*8,W?#0RH')_X<#E&(%F'!KA%Z M] V&=/3+ D"-?"I6W3:#G&4I$(FYQ]+?]"^&^@>S<+L "?(=DX,&S60N8QBI M$.,G8@6+(X-Q2*;%0-O/B-0D1I8/.1S>TS"B'':!?IXE19DD1(7AS+.(60K1 M">ZC0?%DH/-@S'$;4T8%UUERUY4=Y8VJ%L.6#;VR)'LVM7 M6VIQFC(Q878Z(UBW0Z10V+0N_& M<1C-NS17N>"FJO8P"-R MGK,^1S;:.[P<]M)/(T^XHYM;5"L-"Q]*@IQ7D0 H1%L+>I?6F M9>$0)!1#)FHLEG 1WL;(LM :PQ)V,GE" _Y*H;U7%$Z,Q6*JA+>)JTUAJ65F MK'FQL83Y##U38FXFEMXLHY5U;)'%Z$4=51_\HDOG5!9+X&!9SL+;Z/I=T8MPC9 M&8%;9;+#IA7XGG;F[X6>U&<7)5=I?&4UH:K/!1^N04!%]A,YVB3-19R<@,H2 M7888=\*BKCS!#R;G2;O4>G4#).TW7V#:J#8Q60\Z[AH&8$72[C_,R/6!\8;P M;AG3[*B/2%*4YPGT0)1<3ZCRX"^5O?K ?9<8_GRM4]YF'%J>(,A==7E3,D%$ M"0\@+*8Y!Z7'BACD!%7U=(D_U<'/(*.H"ZGC8W6R(;7T;R(T!9LG?(*>K58+ MS,Q#@-"7#'D- U0LI*[QUDDXTS$RE%$,0XGRIL1F"C@!NX&Y\VDX)K--Q<:N M$1P.AF,2IH4YEY+Y\(8-9\M5AR.EN\IH<.403GC#.)1QCR6R4A1#A M\V9I@/^25,#D"^C26$W*3*@94IKF%^%FLLDF6J$P&S$O@ M.UOUN.*EOQNR\&(M68 1KZJN7]=:[44'H+J:<.HS$M*HH"@!$O/P4 M:-_"X M6-4H"O!Q!#F6^S*:ELG )Z46C@B)_%X8@;7RPA=H2',"MA&;RT0H"X5'&"FZ M3&3X244$R8&$Q"V%4$J64<>>L9*V-T2(B3QM>?5*EP@=((5B>M&A= :. MD,5!FMIL7IL>)=3,B3:=HN!,/FN 435?L'C,022>RL(YM20:&7>,?FXJAL+< MY] &@S:*4"+LT;HAYC(VNV*>$\=M,E$S5ETOD/-E9R58(2A53BM/VT]'0E;H MD")73J5+]EW(CD!7\2:WN$I=6;U+UDST5$N]BFB"_S9 V0T<>)R6>*4DS>'' M)$TVPQPD/8I3\+=/D3;D=3;5%L3,@VE]+*PYO F4/1R&&1/&WV:B3CIU&FK* MB@RC%^C44A"PU;*VI_=69&!1Y2P7(*XLSU6C=IW$X6KZ5FA\#IA^)?EXY,G@ M6VQ)X](N0(9?+U+LY3UZ55>>*(/"H61Z,EF\P#S/W)&]G52 6P%- MEX)U%N1SK>24HA<-6:8'D5H!)C8Y!^C&][R 9 D]'<= 5TB]EX3&W"UK0NS6 MKF)%Z#Q;Q%915I,US ML'PG)ALG-(X_*1*1%HYTV9QJ(JDPA#T;A;;-24-@1 M0"0?8TY'Z&ZUA;HR)P3ZF%T".JSS[M$T, ^G^-YZEGR.-LKUT^"1;417';ZV MG*-"Z&9971<:[Q0>\BZ;"-]$NTU:YZC +TG;6M4Q*I#ONV/Z84T](,9'@!(2 M-@FHS_36"%!8NX'YC)M8()FWZT_!.=AHCB9+3LH>*?2E+R MB'SY23DTPLX)6ENR=.D>V;U<@R%<&&K2B.BUT!VS*/*HW=4)G,HQ_=5DN5+M;A+L()V!HI3$Z-?M,9 M4-XD$L/@2%1")W@K]!99AZ:I!"*U@1K.3MEN$R%)E-;D^)+=GH.,)WJ+ ]'>/5.)*^!32/$1!TF ='O MAQW[N_:',]5F2IF+[\2I67"W_NV5+/@L2X/SL B!"UM(_3+LU\"^(N&0P%EP MITH1$..2U"]N1UBMS4^YUG)QIR, &00_X4A>$9X-1RNKLN_*I.1>MJ8BMEM0 MSH0&@XYF1E9)O';*FZ&)C9@LK=^-W7.7U#6L!B-D?443E9Z"#&*>]4O'/CFK M=^K6N1NL\2PWK-?(?UC6B#05J;#2P(2Z=2L01H\[-,Y&22F3D'K8D*_%H:4< M3%%-MKA.RWC"1,T93N@%#!IY1NY9B I8/+D95PG'J&)9N5K'4+<+V!M:Z>%0 M*QV.X$93U"W67>NB:_30X5IM#J(33- 2F(%"L@DPKG-@-\KF6XP1>/H8(_ = MQ@A(75'-]P>!R0V%IEAY[<(P7)DM23%O1;70ODS.RMA4.>;&,;8::]*$Y8 MO[%@VJC.-&FD6,VN0R\:K$+ &AS_/E4T68(>962R)S;YR#,78@T090*Y/H]P MM)GQQ=UY6R(N(9.T_XW4A'".5**PMBP69W5SK''+_JWX#HAU]4@M26G6%\X+K'I*2\J1HRL-LSAB%K)!BBP"&967B]#/I6S"M?'A MZY7:S&?ZJ!?*]XK'_-7NUN;[F/7J53H)C#95QTM>O+\BBJMKD6-Y&RD9,[3% MNHS4>4M)DV[3=4BQ/,YU=D _OK01B%0NIRENB PO!.LD!/B12U'%Z+K@R JZ M>))XRNR*/=X2,RR&'?N2ISA6IG:9OJF'R)ZWEK5/4IH: *K;4M248XL4AK _ MW?JSGO$JY>I^0.HR_5UM[2T*>QKB0,A;Q9* MQA0/D2;**^DF-0:S2$G50G9..H_D6FQW%3^")YV-+I6&K=F=OMFXGBE:9J44 M!(GL[@:P:+>]3-\R)'.(D.J%2LU9H /!?)Y[6Q$48!MV?O MC?^>.]F04EZFA*')6Q>@_0+4P!U.ERWI-EH3&XEO88Y6_R=9SV8ETA@M+]5%0I, :@18,5VNB3WL6KB2-$.*3H@23DM9=;I8 M7Z%P-7\R9S993XTG/QV/J72($S#8ML-H2D&UX82&[:[ GY81>&G"1KGKY"9AUJ/$94(9K%I^:QTLU]$I!%Q5!BA*7&[K+4?H M-0D3E9;YVNSTZG6M2D,7BW''0E::>;/I #%B&)J!"B*RIN:7>/,CI+J-Q^R= M6*79@F;('&? (I//4#HZA@U+D3'J^_%7)AO=BQ\FC&F[CS#OMODM;3UGFU7M MF18E3*$!_6WU$-ZQFV+EE#_Q"K.L2MT.4 _AS4MEX)CC-9;:=HLAFR;$>%D%R+6C MD$&EQ@Q,99BR,%@\C;C&<5(0(]!!#<[]3CJ=F\21Z8ANP97)3:/L=30+._*4 M_F#E*N(R72JC1)%95EMRC\&+U:N>J3C=;:Z_WGW+Y*T[]3RPS*?SU7/;ZG[M M/-/N@S)C$%B,UNVA>]?+?Z="(?6[=SU^3$^+M7%"QEM!2[W'HM&K0X-L07%! MLS[5A[+?-E5P>EG)Z!",213>*,9CJ\T9O :")!HGIJ0)CY7-OM4/ZGY%KLIW MCT6F5Q,G+D<"NZF%4;UO%O_(3]7BS?6/TX^YIPBWW"2OF%A464*0-*WPV.PE2SF9E)*H;)4CP?(9 M:SAPN!,%0C%;<3'O('& L/I$L=$.LKBXIH@[V!A]\S@8!8/$$;0":! M4AJJ?FB]B+D."FD4*R(0[ M=@Q&,A*L1MN:VD14$]WBK(3-0#'H[Q@A#;=!A0#HH.+HWZ4QCF.!0]WXPQ"8 M*385J>H7;(_HZEKV.I))BFAIB9ZVQH''+:4?.?B#$I:0&\(9153)-=EPPT^ X##;AF*-,M3"DAFX@8Y WG$GSV2RGY$= . M] -W2TSL+OE^;\GI[IVRV^&J)N9Q-3ZL;0AI:VB"(3D(TA_HFR+L;1N]"9&W M19%:S:.YXP\#R5*O F^8! CMD.&D>[LCY+$4-ML0XVI/^[(CI2JFDFS+00NT M)'G:RGA9FM9=9[9HZJUH.82-,'94DU=9#I)7FLT@Z0AHO MN9>SIHUV38;!]FX4?:XXZ@1LA1K$OGP7V1MVGO]'\-?@8_#/C?[FZ\Z3_O_< M2;89^:>_Y(;;IQ+(^8<&%&HRG:^QG+K%"3R0>767:_[8L&9N$-ZZ\BJA:RYQ M3';%2IWC.]U9OV%G#8TO;0?P6O"C4<6<^J)>\H=OU]71[1Z1P>PQZF5^EUM_ MW;#UJF&\6B:O8@C6^_2K,-_))JK=LV_5NJ:+WNJ(A$3)U:,G00Q,.;G'J5P\ ML?I<0P*I(]>N+\'MJKWMI2>5B8VI5+*TKCE=!(:[9AIO19LSHC(%MM%&^0:V M[<*I[RY'N)841]L4:L-D9+NE?72A5]T#F\B6J5"N%9; YG]3LP-M)603DS8) MZ^PBKV!HAY0%_%GS5'EZ5=\F7=_#><)::W5A5(V)[;7(X"?;9)HSW+N..Q_- M#Y6EKPS>\#NUS(E4Q$NG10"=K18VZE+&ZA1CD,'N!/F.'"\35P:8K4CP&+%) M/69FDSV#7 MYC#9&'N,Z+U.ZH08%0=3]HO])-52B[@-3-1L"]CW9N0%CYQ53JS_JI+T,*UP M/H/\NQB3D.HBQ$ZW.;HR#((/7O9>OORS%\ST+OPMFI=S7#0*Z.&EZ7]A$CXK M@EY+AOV-DJ^K$7/VRG1,#T,W)9U/FD.EO5 F=^QUU\8!X=_TS1FC6\L!.6V9 MVL^)V)![=2V7T@NJ0I9/+M@C2/JCYJ,62M:#1BT@*4.4%HGD-@-Q(GMK\[\1\O2'OS6)G @<_(JKS"(M%6@ MKP RVY3)5:A3:6\%1X[ ;,TB%$[D5$+2?12QKJW%3?8V4@7:.'FFV-FWZ*W\OFCM_([]%:N%ZOJ;7_; MRAEY053U(.P_D)1 *I6_;9- MO\K$VAITW3\I9XM^A)96I77J@P*.G27S^"'/Z;(M85%MR\ R M*M2E5+>=Y?<(^T I6K"_2G?0=:J#8R'?N3&&84\\9Q%RS!%7$M/Y6+8%I9.> MI3N>=?W*:[+QO&7G)EG W6Z'NL2[M?*\+AY)F\!D@_V%V3IOU7Q^W/YN/7O4 M 6_3)B;Y,+6]>VW)Z4DQCNE'UT>]#54*?:V.T\I0ZJ]!961N%I\XO:TB M2V>V,JR3"&,-RPW31J[A>&4R29C[(1U.*0 JW5,AB'=C:?T1G]1S8%^Q.%SN M1PG)%Z,8CMR[:2M3T9W#ZT_P_9^V=]"M'KR1JG6P<=MHP]2R"VL5;4F&]HJC M5_MXK+(GDC9F:Z$OW8ER)S&$<;KWM>V>Y3V9KG=[T@Q.%U9#69]Q-!K[N#&?EXFD_^:L$W$? M7>4TPUR?$PYS5-K0=>P9.]J\#7NQGB;ND4G-(XSJI>4G*O_!-@5MFM65E<@_ M)J:5;C76*:ULS5?3KJ)0FQK@D]HDDX*QSCP%^3DXZ[WK=>EV/J;9I^" >BU0 MX1%$?M=JX913(,!Q/;LV+?L+K7H:CBDQ3HM0_A9H:9-P:=@\TN30]S5G;J?+ M&VPU6=8V*[MUA_4[KNK-XJ(XT6A*26'(=5FN):*.T;F7"54_KS<^Q(+G5'B0 M%/PE]9_%XS4U"W"?NNB+K==&$JU4&]2A3\+K)="7I.UT7E7B*Y&(!)2T<'A[ MYC:)X2Q&:[ 7'T8C2$ [2#'NCGZ=;3U]^K?D\G@2B5*$V\T4X5ON@'VQ>PW'# M,WVTW)%*'00G(&RE,<@MQYCVE(1=#-M(,(H]#MZ NIF0-'L*LN]85#;[>Y]K MXB,2R@-?GK]YFV/LV0\2670OYD7__Y&%JAX@TMV+59B[S+UW]F?1!+BQQ,AL M[;[ZFF?2CL?&SIYR$1[I%(LZDT>"G$@ T8Y0"I Z86GZ27R++:6TYLF='J*4M3&TZ;0:2-E)6)+9ZY$FN5]Q5KL]8RXSGEW M#64Q;%\1Z;62&U,'MT1KJCC 7BHWCEQ4[HH_H\E;16VU%HLTPAE ^KCVYV/1 M6J& M*6\WHNXJEK=7!;,Y'P5U"T\E.%(74Q)!+[>2G;-,6W9CW54;O<3MG@&"(-^2 M%'=N'JS2&IXC06RN0L0UN/!5T?PK9Y!R-CCY?3< 6T$HAWURRP'\NHMA;>3? MHA3B:-*I9D8TUJN,$8_=QM\SU%%3/RCL7&+3[@MQG_:"=U%.SA[0=.!ST.06Z*"NF*Y985FFA6>7Y=X&B>Q%C/*OM0];,0G M7$L=,Y7_.-;2+TDG;?NFQD3>U">"?ZK41N2BB;"O>1A?ACK'B8S17+K4M7QW MNN;6+;V8*X4D&R2 ;]'+^>+1R_D=>CD;:9-DT"]8U"#D]1T[75]P-''//O=* M_4;!;EBF7Z]0,CA6EI&;E.U>TTH6:)*NHX1&D+#T$"O;S1>3(\1I@>I5S<),@)>NL]+DT'?]X!BFK3%-RDT7W&5/!S;0%M+T M=9XVD" IX (?"IU9;F4-+4,WI3J8\CV7(>KKB/HA6LR1EGQP 41;KD&@5UD8 M.RGK3KDLS^^/AX0B*$>FM?70PTJINP'BX9H.C*U';1VMU9;<^*9I$PDW&ZM+F_&SND-D8_?153$RG&& OM0R MES2D3+S!3A]>-<4;)^]>.N)L;K-A(4.AU-.%B>8+X^<26I-;S5H";J49)!:Z M':43-,90-.>O@)OY)#(U6KG0>\-AHEE&]PAV(E!2C8R5/.+&0HGW5P3^0NO( MC+I]P/7+! CXA0W4H(3UR%;-KS;OUWW?YR3>-+*8C W>:,%>#&WO[*VHQ8,8I,OT"F#:B5P MMQ 5",69#@:3CF3N'80-=T"$QJ2'ZH*+5B:Z@20$HY#.)?J5+O->> UR6Y>] M9-PGF^:_2^"P5&Z' Y&P9^ID:9NFI]/ *V%1K0G: "+<%9'3W1SW<3,@^(OK M2JF]*&L[R/NK =K'?G#5>KM4 MW='O_NJT=YY%HZB@#$^08N;<,EI3*WE!/UUQD\I3?"<1!J'1C?DPC^9L)LYB M!EF)K?=8+[)/%?>1LO6"G9YG)P>#\Y.C MDY^#X=L!?KP8GK\_P!^[P2_]XZ/#H^'';C X>7-Z?C!X-S@9!OV3P^#H9#@X M/SL?#/OX9'#Z!MX^N@@^],_/^_#(Q5N'K^=WKL]/TP M.!_\W#\_#(:G]-S9^=')P='9\8#>A/G>'!\=#.D##(>/G ].WP#F]@_>ZK$/ M3M^=]4]XA?CY[>GQX> \P$=AW4?GYX-?3@_ZKX\_!A?O7[\[@M%DLL$_#H[? M7QS],@C^]O[\Z.+PZ, >AUXR#OIF ./UCV&B]^?P]L71<(@G#MNFZ>&(W9UU M@]>GYZ?O?Z;UO>N?O.T/AWVX#C@L>KY_^+?W,)4Y>ESZX='%V7N8#=?\_@17 M#P_#^' )P->%?Y$1PN_T-_XWA#NZZ+/#\"SP\&[LV-8]:'>/#P+0Q^\O[B0 M[V#,#3CA8U@![(#&.1]'KS'1RXZ73JBAL/^T(>3 MO>"?^S^?#^!*3TYIFCXLYWQ(8'."EW(TA*?D[,\!!$X/!@-<7Y=^/SCN'[V# M!?3A#?@?CW(V.+\X/0$PI4O]F[/^ZE7R% M='N?"SF\&3-M !OXY>B ()K6 M>W%A$ 1/!1>COW\]P*/&%P15](+:-X[X]JY_=(S_[,.@9Q\UY >_'/4198XN M (-A/'@-",#PZ,T1?,!7\!O"VJ.?WPZ#P\$QK/O\8[!!5SWXY>AP<,++UC]U M<*VT'MY< .?,8'IXCLN'%0_>O,$#1@"&LX=MT_Z.AN[5TOWPMN1HF(H0R3@: M(G#_?'K*A./B_9LW1P='"&$MY\C36'2'SV_Q,!#&^TG=D@.M#_R/]?4['@3O%>S!SR5. I2=P[W \.J0Z1V0F]L BP (KH;FHB/J M \X< ;3 [P"6'^^+IUQV@K>*0L9R]L[,Y).)ULZXEB<9VY.(BPDG6*Y;0O== M/DL>S!IWMO&%HCS8:A:DYY.J:[/;A14[6OL=)=P]F>18J'])O1!?LHA$T_'+D& M$9L:8B68M>N0_#U2VT12U:6H*$L?S3*ZI^AHV:W)KQ7]0TQ4&'Y=5*Q3*&2A MQ"61@+PC?SNQP9YP,1[/\\(/'L!+D"\;?CP9MA\/JX?_+W__D6W5HO M']U:WZ%;ZR%$C'WF,KXQ_-G>>D2@[Q"!0/($D?P$A= /+.5V:Z8;,N+Y74IU MN=XRIHR><5EH"U!N2^UBFS$))C;V*LH,X/@HM)V.*7>*/"+W$&)*\,_NNS2; M[Y<+K#@ TM:K!Q)[>K/%KH^TOZ<5?T8"FOOZ[UHB?\2!]A-T@,:OW )>\A6< M'*8_R/'07\%-,[UV=WM/W42OX/%\&\XW\$_W))RK_<>3NL%)#3%"YCZ.ZB&2 MOD?![FL*=MN/@MTW*]C=1L._.'@[.'Q_/ BV[\G$\.;T_!T:%P;_&)P?'%T, MQ+QZ)_3DG\-4RJ8:6;4EU*^E5H$M#BPB\-U4'#\.)Y&4H?@9SC=&1^+=)(IN M;'?(2,NUCMGO'E5#P;4Z<)+V_O6O?WFE(N4G4Q]2$N_AX%>+J]A6^1 0Y9KB MXYTP/'=PIU8?-]$]T W(45$ALR3I+$X9$+1 6O?Z1$W=.B&VQ;*-PIBK,"'K M="6L3'T-4]V*>]BIWX.T2=>14SGI72:>WH#RORK_52*P_.86=[VMW8Z3H2&U MM:7&P\+V?N"J)UZ9<;__(JB6&^.9PL)HB>K<#6I\X[)E^_P7ZC)5P?NCX&(Y M'Z7Q7TC >?E\;^]5TZLKM*.=Y[W=EZYZA#T\G K)CY?T$"])$]=JOQ5=D9YY MH--@VP]"NANZL=<)CMQP(3)1*2GG&@8>H'7KH3JZ94M>SG'Y_^'21^H XP3: MFG8]P;0DXN053KA! ]&[IJE/.\%9M6-1I2S+S=LU5;B%4^7T-ALG(M_>:J!2 M.-.6$3G\T#_090<"[HZ]7V-H\M_='.ZS#E9#14ZK*X$87V?C&;L,.U,+V+CI MDNJVL?2"A*EL2[6,N4F8D$G4%7><,G) U3'*KN]Z]2RWHOH-RG-MA.MNO;%( MF=,\PRNC2$5;=_>XYS&'*78P?G".L8 ZGI"+LU4(#=9)K689^4UB)/F.%"SU M10,\VP$"ZS9/[D;@0+N9376XFSE??Z7*,$U[NYN9V*;V3=IH=N[41O-[#3*8 MC+3.'O,$A?P*,\FTMDD"9_G. MMV_GA_^SNSO(YE$V57'P;OS^+(CSZ6JALBJ8%BJJX-N[I)H'XWRYC++@O2J* M)$V#UT42WZ@@>+5W\&)O?^_5M[N[/_X 0YW(.WEV%!P^^_;9\_WGA\'!\Z,7 MWQ\=/ \NWP<[U^.3'CU\>G$R_G@YX$DOKU^?#4^";W:?/?MP>/+LV>GXE'^ MT0^"<1%E95(E>1:ESYX-SK\)OIE7U?+HV;.[N[N]N\.]O+AY-AX]FU>+],6S M-,]+M1=7\3<__H#?P)\JBG_\8:&J*)C.HZ)4U?]\3Q^LY7Z7.U&:7(#@^-:CWG_1[+UB3<)OW8 /]''.T6[F^1I M#,\./L^325+!01[\\&P"4%O^"FN< KZJPEED@/\_>,[_>."*?\#O].-Q4B[3 M:'V49&F2J=U)FD\_'=\F)>PI3:KUT3R)8Y4=\ZGP7/_WO[Y_OG]X_,,S' =F M+GZDC?LK\*=\DQ>+()\%EX7:?;/*8J"@#U$!6%]]89AM@)"[Z^8&&]OZ39RC M"T4:ID).,0-H'JV62U5,HQ*)XK5*4U7DRWF>!>.Y*J*E6E7)M R#83;=VW(Z M&\:]W]E>C-X'%V^"#_W1J'\^#L87P.U&)^_Z5X/@Y.+]^XOSX&I\Y/EJ,5$%4LD5\'!5'@4'X7??'X0OGW\;/#Z%W,V32NV6RVBJ MCI9 M7> 5/",4&UPGN\%?P_@OW\\)HCNL\+@ AAZ H(T&);E2@6G(*^/@O=1 M,9W+BL, I?9O;=V;:3@,HN 4I. =8$8PS8ME7D0H&H.=:JX"Q-;G^\W.1Y'$19'-Q&Z2J:I#@JZ""Q MXG'# ,U'90DD6WKK?@=4J J[[*0,@*)17X&1RM7D7VI:!55.2X)1 M%F4 &@[N O2VB4KSNQ!_7:[@B(%O!;,B7]"S H]@M<3?(_BC K2 Q5O""DJB M-?QRFB\6 -"R @D8!O^]CXK9,BH(0"H ILC/UB&.[USA.W;],)@[_8Z* %3E M"O_ $? LY7U-3D3Q,@!!.P(=U+Y1\G&TO53J:8,(SRE0GX%[)P"%99%,W66K MGU>P>8"#[,SN)RJ#*/[7JD2]EF$':$[PQK_AUV61WR8HLQ/8*IP%XMTK.O?L!F#-D@VG+0 /0=>9*M+^ DKCIAG7<6:@S9A4X?+H,?G6P5ZP4?2? MJEF2\;I0NN\%H.72K:C\O5)3!W[CA+ZLS)("$ M675T^.W&K>]$/7UX?6!\:6*/C)96$FI;YJBB#250F?$IQ#E#/\BJ(%2H'^$;;#FG? M6?OF\UEM[_ U[ [6\.)H?S^XW'L/J\>#_9@7GX(3? (9^#TVC/O%*E"17/8 >1,2@3H) ( MA>@-L.5_L^Z)O]R00@BPGRI%.P*0H\HW6V6D*!#F\C3X*RV_[.T%0]&1&K00 M3*,,X3O!?Z7351II,$<>9D>HG(&"O,)EQ0;+UEK[@C?438YC Z)I#:IEN@;F MD*X"7]"8S DG(IRBQ$"4M4( X6)5@6(%##56R*23C*'I*H"(X_B9F;K=>^O/ MS.0S4LE1:[TIE&(-JGT)]?4[5/(ZCXH8'S@EB90795TUY>V!2*$S(YL 9@"U M^E^K^(;4)%B"V5C["O;07&F9"YG:P7?'YG7&&0/0"0I*. K:&GY'QXE\>U+B MQ+%:D'0C0*BBR %P?:T5>V.6=M!H";HJX!@<'9R(U6HU0R4M,4Y0F\W0MJ#/ MY1)L?_T!Y/%$K]50J\9^TB4C5H!C@#:B^YQF39,I&U&"LO@$,+\DCY]*WL1& MWG0QZJ8L_:6\BXU!02Q7'4=ZA\=@LYI?YJRY"$=SN&?(HX0B['"P%JTY]"GR M/"KCZ.?@)%HF:-KQOIX*XLI ?$3VKECHI)D@+37A[1CL0"EET/X>PHP[ MA\&.]PRZ80X/#W>?'[YZ\=UA[ZEV/C,[]]7-YH[]W\D6?W5X2(<>+4@[>*H] MW)@]:"HYC=9-C?].J4]QM/:QOE,5 @H '2AS\=QE_QZI.$H%LJMXD50-$KG/ M"G%U0+1JR=;K552M"O@NY$]@&>A_XX.\!]3#@IE"YT\:I.H&_ISG:8(/B&+A M:]G"3CTX3*+L$ZX)5+\JJ5;,F.%M7^E"X1:MJGE>P"'%;)/_O$H*%III=&?9 MS TJ,QD2 "Q'F"Y(HVF*T2]"DD: R@LE43P+_EWE"PYI.9&E7R..Y'NAG[\0 M'-NWUK2S:/YS7NA%3*+IIQM0NK(85+;]MY_*5$ZB3;]PX73T"N 3=;G=2J.C3+CDXCJ+T+EJ7 L;OO]][_N)/QY.\ M *R1H-U^+;+W>XL7WI.3S%U.PKZG_DV#_R/O7P%8V0DW+D!3T?( +)6]_E[8 M*B*,.PLU;_;,%B(1"F,6N*PE9']B)DIZ62+Q+I>@&5?L2&#+/UI&4R#0+\E] MNT'T?(M?">4]1NPI&&(DQK$O'^$W[1%DYQ.JH<;7%"'S@==(-1>_H*^6DY\Y MG\W8+8T>;I@=73^W5$ MN'&O6%G^PO-[N@]8MRK)!060GQK+]"% 1$$IX\-7%5AQB,E69=5TYOC$#EZ\ M0"_V8I7>D#G9Y1]C)/*M(QV\"/*[#,DU638]FV3$@-T#)T:.#U!/%Q%06-1F M#C*51I7VE'H0T_L=R:Q.5"03'7VA]%'PC-IPW&%!S*MFUSEKR4((^KF<_8KX M"\9Y8:5K6##K!!R>461Z:OW&<=6CHL!/Q.3F)CCVFHYQ'XXX0:S4@BU=S*"1 MU9NHD%Y9+3(@JP2+,$]7:.'C"6C_NF9V&HKB(3,!$'E,ZRI(#,EDI=4(:W S M@R03$>#&NH?V88?:&@7] \,G@'KH,Y#WR5T:%8_$- ^W,,TZ<]3"1[CCE8TR M@(T+!BMQ#6446?88,["6%-;R^X M7HK_B.1AX0&S,*^A;SZ#P[RSL:ME>R@*%SDI*WB(99#XI!:-G>Z829V!G1@A MXDX],J7(@S'5G+L+B&5N%HY49DQGD8O'CT3T9AYD.XK=:\Y8 M$P&X\Z;&2F&L2%CLG,XGH-U'QIP!B;-4+.WJRR&>[CCRYE'S#0NG%E%S3[): M%FI)860"(GO050KJ;A'( NI*(_!-X(M@B):*4-Q=M1:%26D%/E #H&T:Q!CX MAO7#S(:>BAJ;L911U5C^)DXOYR0,GODZ;F3./VO"=?BP.$E]V2R.XHAT"9:T M^.-3LND76]BTB9'CCDY7'> M\!*=ME6E52)7TC\XU-ZB,3YAH')LR7X1.4J(M\G)6A.J!$J\+)&DY^5O, X; MM8]$1U15T71.633!%?Z#=%LB)AC-5[QEF',:QFJ1)/M5)28/# "D1/H%C*#*GB/LT$FO66S!OWC.--(\[V.?4H1[S81U $A4:A4/M)'#U.7&,V; MJC2UXJ)M:3A-XMC\FS40Y*:>XN7K)5UXJ;60/1>4VC>B[9Z01$A-Z_#42YOF MQB_?L-Z!>77P*HB\TF[4.6D]$/!4>"5:SD,W%8;-&-X-[=]3KAI6L#FK< LE MWD9)2@QZQHDY/(-Y7;/=&SC@C-DL&X,!D1OLB@DJ6F X&?BJU#Y(('"JC:S' MD:POMV8C643U ?'$(I5,"T-HK6E1OEJ#KHHE9A#M8+H.$&X&)'N++!FCX84< MS%T>.(& TI&-'@?IA39\C,Q"E8:S:P.8U4W\IJ%N8I5,G%3,$J,;P';TH#@H M9Q,H/?O'D0"&V)R\3H\G^^S6,\ZM"LN9I)PAHI3Y?A*E1*C(;Q%'N9@'WC]5 MY [. 1\\YVJP(VSV='QB[*EJ7N2KFSE-(2\&'V"DN(CN@$\Q,&P.45"N0<#N]9&$D) MN\ XSYJR3#+BP@#S(F&10GPBC@MD')A/!C8/YAQW"64T<)TEAZ[N*&_4K1CV ME!NG0HL_S#BX/%P)6U26+XVUKE )M?Z<8>@-T&?)68+P+5FW]9%0]@T?7.6S1,%JA\3^=QXV\2!J'-(FHI<7>:S M8S8IQ*C%!<@CG"[3-@IFK!,3L7I3C;B!% T!YTXF+0Q=USX\-'C2'=K6G%J=9929M.4J;2$-JUU0[V$ ?Y'\W$%UE M,.G4*I?LJ+Z+:,-Y04FP2G-^[6S!S"FT8+4"YJ5[(]9KG,*G3+)3=!-A^-I- M[152MO'GYG),MF:5SV9H85'JW32-DD5(H="C>B2)8A#/K5424]R M(0<$OI,)$S06OFO$^KQX#_6>.;)5KIL1.TWGQ5.0P)U9!83<43+LK;%$46>F-8P\[B9S3@ MORBU]Y;2B1,U:S#>-JDV@Z6N"N/-2XTGS!?HA1)W,XGT=AUMU;2FG.!X:?7> M>D3@G8F$:+NB/&@1GG\K<"RD9<6 MJ+4Y=1>84J_18TK+JV&^SJ5EY<,)C6%$+:SGI\R4DSB*27(QYW/!L_B]#DKL MJ,]NI9<;C*RBQ3*(5V@?]5H","[%<2:+ YE0QW1$J3=0EGF=S.%EE-0#]<>F M\"T$E?D.#'#RM_@QEFYGW#+B8 1NE=D.NU;@>]J9OQ=Z4L,NR6[S]-9:0O68 M"S[D*3!W^I[=5'[L>D M\.^V!N5MQ:&5"4+<]9 W%1,D5/ RF)>:U#%#SD+K.6Z?@3.?(4$4Q#"7& MFQ*?*= $[ ;F+F?1E-PV-1^[)G #.**TE'2,-8M15D)$SINE ?U+40&S+^!+4Q6O"N%FR&G:7X23*>)= M]$)A-6)9E=HD=N.T*'*G10+&,:*DO_ZD='9>(]M(HVM+%H!3A>+Q#"WU:;D& MV]U28'=U-*$Q(G&AL&W5>*[%=K;F<2U*_SALX?NM; %&O*V'?EUOM9<=@.9J MQJ7/R$B3BK($2,U#H%:T;I!QJ6IP%)#CB'*L]Q4T+;.!3THM'142Y;T( NOE MA2_0D>8D;",UKS+A+)0>8;3H52;#QS45I 06EJ[;\K448BEY1AU_QD;>WI(A M)OJTE=4;0R($0$K%]+)#"0:.DL5)FMIMWI@>-=3"R3:=H>),,6O 4;58LGK, M222>R<(UM:0:F7",?FXFCL+2E]"&@G:J2#+LT;LA[C)VNV*=$^=M,E,S7ETO MD?-5;R-:(2K5H%7FW="1E!4"4N+JJ73(?@C94>AJT>2.4*FKJX?DS<1(M?2K M2&+\MT'*,'#P<;;"(R5M#C]F>;8;E:#I49Z"OWW*M*&HL^FV(&X>+.MC97@J"MUK4]N[>F XLI9Z4 265YKIZU MZQ0.U\NW(A-SP/(KJ<>C2 :?8D<9EPX)4FV*#\+9JA"T;F-0J!5;8Y,#HEB5 M>U>@&S0SGKM:-(J/Q#C=R T*I@,>A1+D*FSQ8V.Y;BK)5I[X..+@U38[$'3Y M")"A;PG9"H$:P1!6=W$WFU^^F6L6RG4"6_[1WO_#<_QZF6*OGC"JNA&BC JG M4NG);/$*ZSQ+1_=V2@$>A#0A)>LL*>9:JRG%*!J*3 \CM0%,8G(!V(WO>0G) MDGHZ38&OD'DO!8VEV]:$Q*U=Q8;4>?:(;>*LIFJ8%]@]$K(-4YM'$958M$5C MG;97&HBI3"D/QN#M\E)0VA%@)(.Q)!"Z6^W@KBP)@3\6-T .VZ)[- W,PR6^ M#YZE7*"/81/CBW78I'..&OZ2MJU- M'6,"^;$[YA_6U0-J? (D(6F30/K,;XT"A;T;6,ZXA052>;L="@Y@DP6Z++DH M>Z*P,E^BI[>ZAHE"?BK+*2+RY2?EU @[)UAMV=KE>^3W3!**HB MD,(64[^,^#6XKT@Y)'06VJES!*2X+/>;VQ%5:_=3J:U##9GEIO4:_0_;&I&E(AU66H10V/0"8?:X MP^-LEI0R!:FG+?5:G%K*R13U8HN[?)7&S-21VB I?']I$HT M11/+ZM4ZA[I;P=[11@^G6NET!#>;HNFQ#FV(KC5"AVNU-8A.,D%'8@8JR2;! MN"F!W2R;KS%'X/"/'('?88Z ]!75U5=NKI/=*0+,L];4&_%5HD M9V%O/1SR9)?8B H=17'2^HT'TV9UYEDKQVH/'7K98#4&UA+X][FBJ1+T.".S M/?'))YZ[$'N *)/(]\MB8#U2NJ(:.3K2J$@3%B$[ M9,@BDE%[N03C7,H67)L8OEZIK7RFCWJA?*X(YE_M;&V]CUFO7J53P&A+=;SB MQ:=KHKBY%SFVMY&6,6/;K,MHG0_4-.DTW8 4Z^/<9P?LXQN;@4CM-9U7<I :'"CJ:FG%ND,(7]Y?Z?](RW.7?W U97Z.\::^\PR#O6(BIX%_3+2/KC M98TL2"Y@]*NO)0^$HEFH&5,^1)XIKZ6;]!@L$B5="SDXZ3Q2:K7=-?P(GW0U MNG0:MFYW^F;G;JYHF;56$*2RNQO IMWV,'W/D,PA2JJ7*K5@A0X4]RV'XH]8 MPY=ZC:T6N;5LN]*)3812+&7:U&8Z1TB,Z) -%'=8/.;58L&%"K(2:]]@/97N M5,(3&Y^ VYMO9VLZ&_ XIUDE9>+RYLTWY1(4-#@@VNATKL0)@)S@AM;0TSG3 M'H[=2RRRG)+F$/5=<7]8ADF[8\.9DKTEM]VDWN8];41]!#SD9TI+3!^1MN>:$%V* M[>Y7:!PNW+X91#77E6(S6TO5K I*;T@3:PN-&8X 4D7=9U#/GNCVXFRP11W7 M@C7"0:9'$_BA1P:_09.:T=\A'*W]3[J>K4JD,3I>:JJ$I@#4*+#BNMR2>QA: MO)(R0\I.2#(N2]D$7>RO4+F6/[DSV[RG)I*?3Z?4.L1)&.S:83*CI-HHIF'# M#?33,0+OS!;;;,E+4%E7^ [.%)VP#2_#PYP,F'K _8C$)>(6E_53H$SJO'SB M>LHT;K3U14)%P=01K[O!^% 51W3NCA7IQD:E&^0F9=;CQ*N,*EBU_M8Y6*FS M4PBYZ@)0C+C2]EM.,&H292I?E5NKT^O'M:D,73S&/8M9>>'-IA/$2&!H 2J$ MR)::W^+-SY *6\'L0:QVV8(6R)QGP"J3+U!Z.H<-6Y$QZ?OY5Z8:WPCOV"VQ(U9-I5N!VB'\.:E,W#* M^1IK[;O%E+FL\C1'6$.4YC>(.,3].QGK>OEDC2SB+>;5>0?WD@Y3+>@:^?$2 M085:U*:-,%[5$7+K*.10:0@#TQEF51DJGB7[SYY9#JC M6V@EOF^6OTA^L7D52)J0V2I299:TE%PQ>KEX=IA)TM[7^>O<=DW?N MU(O LIPN-\]MN_MURTR[#ZJ,060Q5K='[J%7_TZ-0IIG[T;\F)]66_.$3+2" MEOJ$3:,WIP;9AN)"9GWJ#V6_;>O@]*I6T2$4DRD\4 T4271.S,@2 MGBI;?:L?U/<5N2;?$S:9WLR<65*0-*_PQ.P- M:SF%M)*H;94SP7*P[*-U,R#K#3>C2$LR!)(2J';6/(Y3_ M:$[;]&>#[5"Y9JJA)I+>V9[GXQ^"-&_6_N384GC,9\XMQRLO;M$^IH!IJ1W-:\>5AJ:? M6BQ3;D."ED4.Q(0[=AQ&,A*L1ON:NE14D]WBK(3=0"G8[Y@A#:=!C0 (4&GR M\\HXQ['!H;[XPS"8&5XJ4K-"2AI[8,?J>MM1T^2K%I_S2C7*=>NK MWUSVZ!3R>K4\&AK2;5>1^E=YMGY8UQ!RK:%)AN0D M2'^@KXJQ=VWT/DS>-D7J=(^63CP,-$N]"CQA4B!T0(:+[NV.4,92VFQ+CJN% M]DU/6E7,I-B6DQ9H2>Y@Z/X@H*$G2Q<%AJ(L\V60MDBU5IK4Z/\@3>FZVGA9 MGXST3WONMNLAJ;/JM9#V G3)"4I MM?4(::/[+)$;(4V4W*M9TTZ[-L=@]VT4?>XXZB1L11K%OOPMLO>\>?YOP?\$ M'X._[_1W7_>>]?_Q*-5F%)_^DAONGDHPYV\:4>B2Z7*+Y]1M3N"AS/%CKOEC MRYKY@O#.E=<977N+8_(KUOH9/^;67[=LO>X8K[?)JSF"]3[]+LR/LHGZ[=D/NKHFQ&AU0DJB MU.K1DZ &YESOZFI2O4CL%MKF&R./6;TWF5-1HR&@VG[Q7&2>JM%W 86:G8E['LS M\H(GSBIC&[^J%3W,:I+/$/\AYB3DN@FQ<]L<'1DFP0>O]EZ]^I.7S/0^^IPL M5@M<-"KHT8VY_\(4?-84O8X*^WL57]QFXJ.H_;4Z6]5"9W[&W' MQ@GA7_7)&:=;!X"<:YFZX41BR#VZCD/9"^I*EL\N.")(]J.6HQ9+MJ-&(R&I M0)(6C>0A W$CRUG*=C FZWWV$F0-_!=Y69'W!%@-71)]L+_[OXAY^L-?VR_[ M VQQ3]51>3P'5JWQ]\ZZAVV__\N^>@I#C8 MFH^U7'CE!ZY],&YO N"$_K<$YILB!F%#R@CV=O(N6B!W&D WX1BP>%YA.PK/ MJ\@S ,B"HLH;'")='>AKB,P^90H5ZE+:!^&1HS!;MPBE$_E2R KA6^ *$JIS MQ6HG[;G9 SXQ^9P*[,^I4W7J%N2Q__*%X'&W.S&V8;WA"LOU!4@.I=O^VE7ZO,^AITWS]I9XMQA(ZK2IOTYDI MY&E,F1"U&NF8U_*P34HLB IP22OEJ<*[VSJ#E%O^U<;V86L6+W&Z<::"858 MJ:\DN>F\.MF.M*BN96 ;%;JE5%\[R^\1]8%1M.1XE;Y!U^D.CHU\%\89AG?B M.8L0,"?<24S78]DK*)WR+'WC6>AW7I.-EQT[-\4"[G9[=$N\VRO/N\4CZU*8 M;+*_"%OGK4;,CZ^_VRX>=<+;K$U(_C:MO2>]DM/38AS7C^Z/^A"N%/E6'9>5 MH=9?.S0O \OHW*P^<7E;39?X?L_'CS'L'KP1KK6 MP<;M11NFEUW4Z&A+.K37'+U^C\ZM'VM@-6U)CG>_L'+BR?R'5]N">7P>G&:JCK M,XTF4Y\V%HM5)N6_)=M$?(^N[&1)KXCDRZ/ M,*:7UI^H_0?[%+1K5G=6HOB8N%;">JY37MN:;Z;=)I%V-< GM4LN!>.=>0GZ M?@A.Z:X$:CR#QNUX+IYT"(8X;V;5EV5]HU;-H2H5Q6H7R MMT!+BZ.U$?/(DR,_UERX-UW>8ZO9NK%9V:T[K'_CJMXL+HH+C694%(92E_5: M8NJ8G7N34??SYL6'V/"<&@^2@;^F^V<1O*9G >Y3-WVQ_=I(HY5N@SKU262] M)/J2MITOZD9\+1.1D)(6#F_/W4MBN(I1+F3$'$)[)LPMY"(4/A+SG.VS5*,Y M30Z/DUCC_((#(JK50)(>;C__->:&<4-H@R^_A? K4.]K_;?_GJUYK/ MDTF@2E5JMUQ&4W4$]L'N'8 ;GNFCYXY,ZB X!V4K3T%O.<.RIRP*,6TCPRSV M-'@#YF9&VNP%Z+Y3,=GL[WWNB8]$* ]\>?GF;8ZIYRC(9-%[*2_Z_TTL5NT! M(3V^6H6URWSWSM$\B4$:2X[,_N'QKPF3;CHV?O:+!,*^M"%,G/OFM])PPI1);E4^5:O-@SZCK7W;6TQ;#WBLA=*Z5Q=?"5:&T=!SA*Y>:1B\E= MBV>T1:OH6JWE,D]P!M ^[OSY6+76)0W<0:/> L,X$L;4*"??@PE?%\J_!(.=J M<(K[[@"U@E(.^^0K!_#K$-/:*+Y%)<1)W*M71K3VJTR1CMV+O^=HH^9^4MA( MBG!?[@7ODY(N-Z/V%(^=^12,N#B4>D!=VRETJQAT M"*(W7"=8M=0WZ+P^)X..RG>*E:GEP:B_"4H\'"BNI[29!F:JN^QU2Y%7)-5> M?6NZ62'\0I)I7,1:S:GZ4M]A(S'A1NF8Z?S'N99^2SJYMF]F7.1M]T3P3[7> MB-PT$?:UB-*;2-ZGN]>:$[=\HN%4LBR00/X&J.9-4T"]9U2#B]0,[H:\XFKQG7WKE_D7!;EJFWZ]0*C@VMI&+5]U1TUH5:)9O MXX1&D;#\$#O;+99,WWJKSU;@!\<&=S5PV/0^A[?C9P1.S; MP*R,K^%TED3]1LJ2HZ#-M"[X9EHH $C>*/)_POA0W]YJJ",' ZY(=?IN2+-J MTJ:26U9_A>6+$V[=J9@[HGCMW&>VO;$$7K;$MR*67G<0/",LZ4_ETHK,U8BI M7D*2[%M$C;E;.-?MW#IEBM>\P=PL2PUW&[$K&]:VS1_T-J/;/"& E4I](@%) M7R"(\@G=?RF"RKUE7(?*)4^WK[ -/KG(.;!)53Q\JF\"IY9^6> M2W/C'\\@;95I2KYDT7W&=' SUP+:NP!UG3:P(&G@ A\J75EN=0VM0[>5.ICV M/3<1VNM(^A%ZS)&7?' 11'NN0:%7190Z)>M.NRPO[H] 0A64,].Z[M##1VN, MD=T'3MA2-Q2KY,8?9H9>&*PPPEKHJI0RID&BP0Q.F,HF_-?0)MEG)@>K=SHO068 MZ);1=P0[&2BY)L9:'7%KH\2G:P)_I6UD)MT^T/I-!@S\RB9J4,%Z8KMFN7?* M6Q:61G?41=*A0@%51&/6P91RQD0HS'E MH;KAHM6)[J$)P2AD&=JO+:7 MIN>SP&MA4>\)VH(B?"LBE[LYX>-V1/ 7%TJKO:3H N33]0#MX[X6^FJ^#ZCX M%%8Y*IV\AMIMMJ&K]=ZN[HW_[J7.\\3R9)116>H,4L^,IH MS:WD!?UT+4PJ3_&9))B$1B?FXSRZLYDYBQMD([4^8;_(/G7<1\ZV%XQLWXP- MF8VZA8?IEA*9(5C\QTY+&;E0S=/ \ ES#WO9R&![PI:0;SDF#U1W%MT=!W]Q MY-]>T#\["_[W>G U'EZ<7P4G%^#\['0?_\-!B>CP>CR]%@W,_$3C#XX#5Y_I/=D?/@"/\FH.%S0/SFY&)WV837!A^'X':WFK/_A MBL<>!%C !^%=0]'H\%/ M%R?]UV/TS MF.AZ!&]?#<=CA#ALFZ8'$+L["X/7%Z.+Z[>TOO?]\W?]\;@/QP' HN?[IW^Y MAJD,Z''II\.KRVN8#==\?8ZKAX=A? # ^8!7A3\1:.$7^AO?&\-Y7?7Y 7AV M/'A_>0:K/M6;AV=AZ)/KJROY#L;< 0B?P0I@!S3.:'!U"7,8H#BX(JL3@+B3 MG5Z<7.,C5[V00-0"[ ]]@.P5_]Q_.QK D9Y?T#1]6,YH3&ASCH)3+P>CJXAS0E [U+\[ZZT?)4P"VT.G] M4LSAS9AI ]C 3\,3PFA:[]65(1"$"BY&?_]Z@*#&%X14](*Z-X[T]KX_/,-_ M]F'0RX\:\X.?AGTDF>$54#",!Z\! Q@/WPSA [Z"WQ#5#M^^&P>G@S-8]^AC ML$-'/?AI>#HXYV7KGWJX5EH/;RX .#.:GHYP^;#BP9LW"&!$8( ];)OV-QR[ M1TOGP]L2T# 7(98Q'"-RO[VX8,9Q=?WFS?!DB!C6 4>>QI([?'Z'P$ <[P_/ M+3(;5G4Z )0E-G(V?#\TR/6A_Y'^'A$X<*=X#F8N>0JH]!S.'0 KXZ9WP&[ M>0BR"(+@:F@N E$?:&8(V *_ UI^?"J9GN1L MSQ)N)IQANVY)W7?E+$4P&]+9YA>*\6"[69"=3Z:NK6X74>SH56S8/16(YF" M85M(=@"NR>$YU0Y(;"4-RZ<:T>;"ZY!PLB_)8L=75YG"SE]3I6\-9W\6&1YR MWXQNV$[:V1:'.3Y&<:%X#<&5^02SZF>$;,3N8GR-HCDN2(2%XLCE9+ M+.(& 7;\&SF<^RUV>_+R$ZWX%]3TN*__1TODCSC0488QI?38[8DD7P'D,*-< MP$-_!?W,Q>H_FVN!O@]')\&H@ M#JM'82=_'^?2B-*HJAW)4QW5W[;=JFC C]/#^2R*$RGL?POP33$T\SBE=SL' M/7)[1:;0V9[\I/IN">ES #XS=HJ7E1["H1R1QG' M3F*3.[C3_8RO)3W15SJCG4*.'C)9G,8*=)^Y"5C&:N9V7K"7UMJX]D)%&?G[ M:HDZZM=P?FPXA^?-9=N MQ5(UO[3=]+F/A->XV;_1#BS+G>E<8:NI3/4>AS2^_XK=9.KX'H87*T7 MDSS],^DWK[Y[\>*X[=4-QM'S[_8.7[G6$=Z*X/2<_>.0?HN'I)EK_08+W>.; M9:!S9;&?UO$X?.-%+QBZ"1CDH5+2(#,*/$0+F\D/^A*,]X+)^!TRMT<7]+\"I20NG;^1#-DY,OKMY M>ZT5H6W,/T0/JH28.)C;[$;D]JN_1\&@GVG;J MK6V?G.L(O,9TU ;S\ 7?(LN)7SW,R%I@=I7.T.)V5S5&@YTGZW4;_K4;4LY$ M!I;ZHBESW0B!G7#CQU$XT&UFD\&5X-60Q+FAT;>U::W/;-A;]*UAWNW%FJ+?E MA^QZ)G$>FZZ3>F)W,_T(D9"$A"18 )2L_/H]%P I2I9=-XVS22?)6+9 /=] M[[D@3O[1:CW/9SR/1<+^??7ZG"4J+C.16Q9KP2U&%]+.V)4J"IZSUT)KF:;L MJ9;)5#!VU.[MM;OMH_U6Z_0$6YV%-2H?L4%GO]/O]@>LUQ_M'8YZ?7;QFNW^ M>G7VV$U^]LO9U6\7SSW1BU^?GK\Z8SNM3N?=X*S3>7;US#_ [CUVI7ENI)4J MYVFG\_S-#MN965N,.IW%8M%>#-I*3SM7;SLSFZ5[G50I(]J)379.3V@$GX(G MIR>9L)S%,ZZ-L#_M_'KUHG6(&5;:5)R>=*K??NY8)+PQY[JUD(F=C7K=[H_'!4\2F4];J9C8T;!]>+@:TG(Z MJ\>4%VVD1;!+:M+*IU$Y7;UH1G,EV.'EW)3!CV M1BS86Y7Q_%'D1_#;""TGCX[=;",_"FP-\:RXMBV>RBDV)UZ/O?RC(/IXC8A? MUL,C]W4AG'1CE2:8^_QZ)L?2LF&[=](90VN%E\YM_M,.*8>LP,>IJ#8=*YT( MW8I5FO+"B%'U1Y/)?5";>4*DE1A/X+/K.B=FUS5.(PT%$F&-GZ2B/!?:RIBG M0718.TS?P^R&"L*NE3HZ-KEC%YC.JJRB>W371I_=>#&4(O2&]60V94;'4'1: MS%H4HEW\OQ;7PP1JZ;7?%],=V =!\E+S8B;CG8JM1)HBY]2M?]^*/NNT#>GK39RFD5G89#MO#H-3BCQ3;,$_OBVIU2T@< M]8[8U4SJA#V9B[P4COTO09CV^4WI#Q%[\QN#^?K]+T9ZM]_K/V9'@V%KT.UV MOQC93.;V8SM6V3@)A'ODE*R[^@$;K[F.9VP_8A1 GU'X M.TB>T-0Z&*1!8DVE78YF,DE$C@G_^N&PWQTY7'[8>BVCO<8^=RC!2P9&=*YT)C%YY$[+*45K!!]W,Z_AKE M=UQKD2/ ?F;=@^[PB#T4H:_$ON<\D5C-\X2]1/U(!>#@Z.\G$P0EQL6JS(W(F56L;MC(F*\>.(R1QS\US$;JJ#X32]T*+@83W9: *%Y=/5 M\TL1EQI%-ICP^34P;PZPCOTS::&4*T"X-(JPHG!?8B"4. MW_OD-_#)+R(%-!=4LWXNTR7KNTE=MDLPCF29BW09L08'#4K$\%;"*ZU 7&Q= ME-J4')[C2+\54VELT,FE!7'7P>#+"Z4S=MD"CVMSWJ@V&PP&K?[@:.]@L*:/ M[7NMZ#.!F .SL1! M)H%D35[6I]?V.>@=1GL'>\R@F<&CM15NJ&E)%,H,DA@+K ;NN69SGI:"_;-+ MK54!QMPV-WS"28\U*\G).'"^UJ1TC,*9T9=90XJ 4N!E!J(6]+47'1SVHF%_ MOV(1?#3W7"-V@2U?^"W?A2UK_G=-"06'39P:TR6IEI9O6;?F5F&0K:ND3>$9 MQJ+;]G&BKJ]G/G17+LRT@)TU5I$+&K;5;.U UA-M!"8V&PN2Q*!-VO#FRW)L M8BT+YX%/IEJLA1YWVMP(0 [53M<Y6LL'P>KBSP6>'*G.,0A98-"YC2./[W! M-84YN0-"8%]*BIGTD2PN=(6@,_@PV)WER!1G) M"182X9J("1JYA"(,JUUUHVWA[X7WX!DNYCU[6P F]@V,#&QCKO/.,VN,)&F3 8;C/J[R!-)HE M)JHC;7.K)Z$&T?-ZVZ=+ !?D2L$1^(1Z?, @ \()!(I=C-SD\K3S*S@/Z":F M\N Z?% [5"Q$XKPI/&QFJWC%_N;SFD'45HEYAOBHE)-0I"<@FXHYISSIGL&= M0U+^@VP3DH'QF9%2PHTT%-T1BM7L[>GG>R3<.Q)4J8.?!X>M[,M16T+E8E.1 MEPB$7!CG(I2T#*AP6];E/!53[A(ACR$LS7*/,0:L8U0>IO$2GSD@>IA$6U5' MWP;N/,ZDM;ZXE\[=E);@EZ=A/0*7J@^MQI3J86.+^^P97)Y"$IV#511Q,L9N M;,)C(Z%\(E144'X;WS16LT8#+A+]HN_>=S]6GW(JDF6A?%<54(4WY1 F[ MO4?85^ EA5FLX(CKI*"Z"S$'HK5C=:2"A'E%< RPV6&Z6A42D0!X! M9Z\AVI"R*="F7.;&@H^ED\V-4_OEFO2&2H*V;D/8#Z,N-W$,[W.X;@S'#.ZS M400%9918N%56YY#:([VHZ:ACGG_096'C)1TCP,N W>COB>8E-.YT M1"_5@&4C5$ZEIT!Y'T/BS:A<(Z>4F>/<5W7" ,0P,K"@9,HA+&JU#VKF3_.I M!:%;*<1%D84$5 M-QE'==:LRBDP]A8B_A!$S64B:)C B7:NQMU!2(Q83>7*]XB!B4B5!C2\?#'.6R\+#('RADE!9"WF#^5(&,0;"KTD*S MW/J&]L'>-7Q*:-VX#K#VXM[='@BO0@ ??I_2^]&0[?N]LD#T.-:Q%AI'DK8O.^ M1<&GHC76@G]H\0DD&_%TP9Q1_S]L9?^[-!5B1 M_A2,4A6:#X",5:0AS[B>QH>_&M-3S)YHE0%T(3'$OO^6K@FJ6_%U%!,U,$.5 M%<9$=N[A7>EHC_T9$X):?B^C?\J,2'S0(D"M$:L#U>:98:-L_+G3SEN0DR9L MID7=U+X"(&;[W=[N^/'NT+UA>%O7&G:)?6Y]VQ$P'STIC:BYG4B=U0<\=$A= MGU$W^IO[P.X&9;3_CI]PP'WN*M!K[^CUF?RKG XU7?GT/;/3J6OB$N4.2H.V M>9+) "A"@Q>XHK.JJ=*N$(;3!=0S941M(,@7%)@$]B[#<=]!C6\VW@EY"5P= M=[(V2_DJUJICWV\M=+Z]NU_#X:??_6I<4;ISEP? ,/\5\$NKJ;T&?M,FVK@N M\Q5)_U4R]0 FZ9@.>TVWER)V+I!X(@3R#)\OZ%8M2NK+5,W-!W_L<:$*H2)V MT3YK?[V&>P =_77]/,0]L+]VI;+_B5&UL4$L! A0#% @ V$-F5GF?W0=U! ^24 !4 M ( !0@D &)L<&@M,C R,S S,#-?<')E+GAM;%!+ 0(4 Q0 ( M -A#9E:N+5MSUQL !'/ 4 " >H- !B;'!H+3(P,C,P M,S S>#AK+FAT;5!+ 0(4 Q0 ( -A#9E:F-\.#0$ .=M 0 8 M " ?,I !B;'!H+3(P,C,P,S S>&5X,3!D,2YH=&U02P$"% ,4 M" #80V96T3)Z15XT "<[0 %P @ %I:@ 8FQP:"TR,#(S M,#,P,WAE>#1D,2YH=&U02P$"% ,4 " #80V967@>#H8\+ !%+P %P M @ '\G@ 8FQP:"TR,#(S,#,P,WAE>#5D,2YH=&U02P4& / < !P#7 0 P*H end